US3334100A - Amino-lower-alkanoylanilines - Google Patents
Amino-lower-alkanoylanilines Download PDFInfo
- Publication number
- US3334100A US3334100A US23919A US2391960A US3334100A US 3334100 A US3334100 A US 3334100A US 23919 A US23919 A US 23919A US 2391960 A US2391960 A US 2391960A US 3334100 A US3334100 A US 3334100A
- Authority
- US
- United States
- Prior art keywords
- acid
- alpha
- acetyl
- dimethylaniline
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims description 35
- -1 halogen radicals Chemical class 0.000 description 92
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 62
- 238000000034 method Methods 0.000 description 57
- 150000003839 salts Chemical class 0.000 description 45
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 40
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 38
- 239000002253 acid Substances 0.000 description 34
- 239000002585 base Substances 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 15
- NRPTXWYBRKRZES-UHFFFAOYSA-N n-(2,6-dimethylphenyl)acetamide Chemical group CC(=O)NC1=C(C)C=CC=C1C NRPTXWYBRKRZES-UHFFFAOYSA-N 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 13
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 10
- 125000004432 carbon atom Chemical group C* 0.000 description 10
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000003960 organic solvent Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 8
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 7
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 7
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000376 reactant Substances 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000001450 anions Chemical class 0.000 description 6
- JEHKKBHWRAXMCH-UHFFFAOYSA-N benzenesulfinic acid Chemical compound O[S@@](=O)C1=CC=CC=C1 JEHKKBHWRAXMCH-UHFFFAOYSA-N 0.000 description 6
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 6
- NLGKRVNANIZGNI-UHFFFAOYSA-N n,2,6-trimethylaniline Chemical compound CNC1=C(C)C=CC=C1C NLGKRVNANIZGNI-UHFFFAOYSA-N 0.000 description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- RNXVXXXZBIXZMS-UHFFFAOYSA-N (4-aminophenyl)arsinic acid Chemical compound NC1=CC=C([AsH](O)=O)C=C1 RNXVXXXZBIXZMS-UHFFFAOYSA-N 0.000 description 5
- FPQQSNUTBWFFLB-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)acetamide Chemical compound CC1=CC=CC(C)=C1NC(=O)CCl FPQQSNUTBWFFLB-UHFFFAOYSA-N 0.000 description 5
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 5
- SUGZATOHBPXTDV-UHFFFAOYSA-N 2-nitrobutane Chemical compound CCC(C)[N+]([O-])=O SUGZATOHBPXTDV-UHFFFAOYSA-N 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 5
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 5
- UPDHOTIATMFGCI-UHFFFAOYSA-N butylarsonic acid Chemical compound CCCC[As](O)(O)=O UPDHOTIATMFGCI-UHFFFAOYSA-N 0.000 description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000003589 local anesthetic agent Substances 0.000 description 5
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 5
- BVXCVHRMIDFOLY-UHFFFAOYSA-N phenylphosphinous acid Chemical compound OPC1=CC=CC=C1 BVXCVHRMIDFOLY-UHFFFAOYSA-N 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- HYISVWRHTUCNCS-UHFFFAOYSA-N pyrene-1-carboxylic acid Chemical compound C1=C2C(C(=O)O)=CC=C(C=C3)C2=C2C3=CC=CC2=C1 HYISVWRHTUCNCS-UHFFFAOYSA-N 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 4
- 229910015900 BF3 Inorganic materials 0.000 description 4
- 101150065749 Churc1 gene Proteins 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 102100038239 Protein Churchill Human genes 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- YTIVTFGABIZHHX-UHFFFAOYSA-N butynedioic acid Chemical compound OC(=O)C#CC(O)=O YTIVTFGABIZHHX-UHFFFAOYSA-N 0.000 description 4
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 4
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000012280 lithium aluminium hydride Substances 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- UFFBMTHBGFGIHF-UHFFFAOYSA-N (2,6-Me2C6H3)NH2 Natural products CC1=CC=CC(C)=C1N UFFBMTHBGFGIHF-UHFFFAOYSA-N 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 3
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- VBSTXRUAXCTZBQ-UHFFFAOYSA-N 1-hexyl-4-phenylpiperazine Chemical compound C1CN(CCCCCC)CCN1C1=CC=CC=C1 VBSTXRUAXCTZBQ-UHFFFAOYSA-N 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- OVFUUSPKWADLNJ-UHFFFAOYSA-N 5-methyl-4-nitro-2-(4-nitrophenyl)-4h-pyrazol-3-one Chemical compound O=C1C([N+]([O-])=O)C(C)=NN1C1=CC=C([N+]([O-])=O)C=C1 OVFUUSPKWADLNJ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 241000700198 Cavia Species 0.000 description 3
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 3
- 239000004380 Cholic acid Substances 0.000 description 3
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 3
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 3
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
- JACRWUWPXAESPB-QMMMGPOBSA-N Tropic acid Natural products OC[C@H](C(O)=O)C1=CC=CC=C1 JACRWUWPXAESPB-QMMMGPOBSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 229940000488 arsenic acid Drugs 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 235000019416 cholic acid Nutrition 0.000 description 3
- 229960002471 cholic acid Drugs 0.000 description 3
- 235000013985 cinnamic acid Nutrition 0.000 description 3
- 229930016911 cinnamic acid Natural products 0.000 description 3
- 235000015165 citric acid Nutrition 0.000 description 3
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 3
- KTLIMPGQZDZPSB-UHFFFAOYSA-N diethylphosphinic acid Chemical compound CCP(O)(=O)CC KTLIMPGQZDZPSB-UHFFFAOYSA-N 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 3
- FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003456 ion exchange resin Substances 0.000 description 3
- 229920003303 ion-exchange polymer Polymers 0.000 description 3
- 229940045996 isethionic acid Drugs 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 229960002510 mandelic acid Drugs 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 3
- VLAPMBHFAWRUQP-UHFFFAOYSA-L molybdic acid Chemical compound O[Mo](O)(=O)=O VLAPMBHFAWRUQP-UHFFFAOYSA-L 0.000 description 3
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- MLCHBQKMVKNBOV-UHFFFAOYSA-N phenylphosphinic acid Chemical compound OP(=O)C1=CC=CC=C1 MLCHBQKMVKNBOV-UHFFFAOYSA-N 0.000 description 3
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 3
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 3
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- 235000002906 tartaric acid Nutrition 0.000 description 3
- 231100000041 toxicology testing Toxicity 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- ILLHORFDXDLILE-UHFFFAOYSA-N 2-bromopropanoyl bromide Chemical compound CC(Br)C(Br)=O ILLHORFDXDLILE-UHFFFAOYSA-N 0.000 description 2
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 2
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- OJGMBLNIHDZDGS-UHFFFAOYSA-N N-Ethylaniline Chemical compound CCNC1=CC=CC=C1 OJGMBLNIHDZDGS-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N Picolinic acid Natural products OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 241000906446 Theraps Species 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 2
- 150000008041 alkali metal carbonates Chemical class 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 229940000489 arsenate Drugs 0.000 description 2
- 229940125717 barbiturate Drugs 0.000 description 2
- JEHKKBHWRAXMCH-UHFFFAOYSA-M benzenesulfinate Chemical compound [O-]S(=O)C1=CC=CC=C1 JEHKKBHWRAXMCH-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- KTLIMPGQZDZPSB-UHFFFAOYSA-M diethylphosphinate Chemical compound CCP([O-])(=O)CC KTLIMPGQZDZPSB-UHFFFAOYSA-M 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- MLCHBQKMVKNBOV-UHFFFAOYSA-M dioxido(phenyl)phosphanium Chemical compound [O-]P(=O)C1=CC=CC=C1 MLCHBQKMVKNBOV-UHFFFAOYSA-M 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 2
- UPMYGNDFABDISL-UHFFFAOYSA-N n-(2-chloro-6-methylphenyl)propanamide Chemical compound CCC(=O)NC1=C(C)C=CC=C1Cl UPMYGNDFABDISL-UHFFFAOYSA-N 0.000 description 2
- 125000004971 nitroalkyl group Chemical group 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
- 229940075930 picrate Drugs 0.000 description 2
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 229940048084 pyrophosphate Drugs 0.000 description 2
- 229940005657 pyrophosphoric acid Drugs 0.000 description 2
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 2
- 150000003460 sulfonic acids Chemical class 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 229950002929 trinitrophenol Drugs 0.000 description 2
- BGJSXRVXTHVRSN-UHFFFAOYSA-N 1,3,5-trioxane Chemical group C1OCOCO1 BGJSXRVXTHVRSN-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- ULTHEAFYOOPTTB-UHFFFAOYSA-N 1,4-dibromobutane Chemical compound BrCCCCBr ULTHEAFYOOPTTB-UHFFFAOYSA-N 0.000 description 1
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical compound CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- JTYPATHQWVWUDX-UHFFFAOYSA-N 2,6-dimethyl-n-propylaniline Chemical compound CCCNC1=C(C)C=CC=C1C JTYPATHQWVWUDX-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- RJICLMDXEDUMAK-UHFFFAOYSA-N 2-amino-2-ethylbutan-1-ol Chemical compound CCC(N)(CC)CO RJICLMDXEDUMAK-UHFFFAOYSA-N 0.000 description 1
- NXBPLYWSINFZHW-UHFFFAOYSA-N 2-chloro-n-(2,6-dimethylphenyl)-n-methylacetamide Chemical compound ClCC(=O)N(C)C1=C(C)C=CC=C1C NXBPLYWSINFZHW-UHFFFAOYSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-M 2-furoate Chemical compound [O-]C(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-M 0.000 description 1
- SEAMRWZKMYUKOI-UHFFFAOYSA-N 2-methyl-2-nitrobutan-1-ol Chemical compound CCC(C)(CO)[N+]([O-])=O SEAMRWZKMYUKOI-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- IAPWHWRXRHOCAR-UHFFFAOYSA-N 3-chloro-n-(2,6-dimethylphenyl)-n-methylpropanamide Chemical compound ClCCC(=O)N(C)C1=C(C)C=CC=C1C IAPWHWRXRHOCAR-UHFFFAOYSA-N 0.000 description 1
- FEJLPMVSVDSKHJ-UHFFFAOYSA-N 3-methyl-1-nitrobutane Chemical compound CC(C)CC[N+]([O-])=O FEJLPMVSVDSKHJ-UHFFFAOYSA-N 0.000 description 1
- RXPKOTQRDGEKFY-UHFFFAOYSA-N 3-nitropentane Chemical compound CCC(CC)[N+]([O-])=O RXPKOTQRDGEKFY-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- LLQHSBBZNDXTIV-UHFFFAOYSA-N 6-[5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-4,5-dihydro-1,2-oxazol-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC1CC(=NO1)C1=CC2=C(NC(O2)=O)C=C1 LLQHSBBZNDXTIV-UHFFFAOYSA-N 0.000 description 1
- NVRVNSHHLPQGCU-UHFFFAOYSA-N 6-bromohexanoic acid Chemical compound OC(=O)CCCCCBr NVRVNSHHLPQGCU-UHFFFAOYSA-N 0.000 description 1
- NOPKNBDBHMWPEF-UHFFFAOYSA-N 6-bromohexanoyl bromide Chemical compound BrCCCCCC(Br)=O NOPKNBDBHMWPEF-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000234282 Allium Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 241001024304 Mino Species 0.000 description 1
- PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
- AFBPFSWMIHJQDM-UHFFFAOYSA-N N-methylaniline Chemical compound CNC1=CC=CC=C1 AFBPFSWMIHJQDM-UHFFFAOYSA-N 0.000 description 1
- ZTHRQJQJODGZHV-UHFFFAOYSA-N N-phenyl-propionamide Natural products CCC(=O)NC1=CC=CC=C1 ZTHRQJQJODGZHV-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- OCBFFGCSTGGPSQ-UHFFFAOYSA-N [CH2]CC Chemical compound [CH2]CC OCBFFGCSTGGPSQ-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 150000007656 barbituric acids Chemical class 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000013213 extrapolation Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000012433 hydrogen halide Substances 0.000 description 1
- 229910000039 hydrogen halide Inorganic materials 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- AJLHOOOTXXVJCZ-UHFFFAOYSA-N n-(2,6-dimethylphenyl)formamide Chemical group CC1=CC=CC(C)=C1NC=O AJLHOOOTXXVJCZ-UHFFFAOYSA-N 0.000 description 1
- HRUQHSNFWGFGGR-UHFFFAOYSA-N n-(2-methyl-6-propan-2-ylphenyl)acetamide Chemical compound CC(C)C1=CC=CC(C)=C1NC(C)=O HRUQHSNFWGFGGR-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical group CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OAPVPGPVBZRARK-UHFFFAOYSA-N n-ethyl-2,6-dimethylaniline Chemical compound CCNC1=C(C)C=CC=C1C OAPVPGPVBZRARK-UHFFFAOYSA-N 0.000 description 1
- BXXYPSIZHJBXBB-UHFFFAOYSA-N n-phenyl-n-propan-2-ylpropanamide Chemical compound CCC(=O)N(C(C)C)C1=CC=CC=C1 BXXYPSIZHJBXBB-UHFFFAOYSA-N 0.000 description 1
- BGUPWXNCOACHRQ-UHFFFAOYSA-N n-propoxyaniline Chemical compound CCCONC1=CC=CC=C1 BGUPWXNCOACHRQ-UHFFFAOYSA-N 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- JDVPQXZIJDEHAN-UHFFFAOYSA-M succinamate Chemical compound NC(=O)CCC([O-])=O JDVPQXZIJDEHAN-UHFFFAOYSA-M 0.000 description 1
- 150000003455 sulfinic acids Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- JACRWUWPXAESPB-UHFFFAOYSA-M tropate Chemical compound OCC(C([O-])=O)C1=CC=CC=C1 JACRWUWPXAESPB-UHFFFAOYSA-M 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
Definitions
- the 2-hydroxyethyl-tertiary amino-N-lower alkanoylanilines hitherto known have all lacked any further substitution on the l-carbon atom of the Z-hydroxyethyl group.
- R R and R each independently. represents hydrogen; lower-alkyl, lower-alkoxy or halogen radicals which can be the same or different; R represents hydrogen or lower-alkyl; R and R each independently represents lower-alkyl or the hydroxymethyl group; and Alk represents lower-alkylene.
- R R R R R R and R represent lower-alkyl radicals or when R R and R represent lower-alkoxy radicals, they can have from one to about four carbon atoms and can be straight or branched and thus stand for such groups as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, and the like.
- R R and R represent halogen atoms, they stand for any of the four halogens, fluorine, chlorine, bromine and iodine.
- a particularly preferred class of compounds are those in which R and R represent lower-alkyl radicals and R represents hydrogen.
- Alk represents a lower-alkylene radical which contains from one to about five carbon atoms and can be either straight or branched.
- group CO-Alk includes such groups, inter alia, as
- the compounds of Formula I are prepared by reacting ice a halo-lower-alkanoylaniline with a Z-hydroxyethylamine (R and R are lower-alkyl), a l-hydroxymethyl-l-loweralkyl-2-hydroxyethylamine (R is lower-alkyl; R is hydroxymethyl), or a 1,1-bis-(hydroxymethyl)-2-hydroxyethylamine (R and R are hydroxymethyl) as illustrated by the equation given below where R R R R R R R and Alk have the meanings given above and Hal represents halogen.
- a preferred method comprises heating a 2-hydroxyethylamine, 1 hydroxymethyl-1-lower-alkyl-2-hydroxyethylamine or 1,1 bis(hydroxymethyl)-2-hydroxyethylamine with a halo-lower-alkanoylaniline at a temperature in the range from about 50 C. to 150 C. in the presence of an acid-acceptor.
- the reaction is preferably carried out in an organic solvent, inert under the conditions of the reaction, for example methanol, ethanol, propanol, acetonitrile, benzene, xylene and the like.
- the purpose of the acid-acceptor is to take up the hydrogen halide which is split out during the course of the reaction.
- the acid-acceptor is a basic substance which forms watersoluble by-products easily separable from the main product of the reaction, and includes such substances as alkali metal salts of weak acids, i.e. sodium carbonate, potassium carbonate, sodium acetate or sodium alkoxides.
- the acid-acceptor can also be in the form of an excess quantity of the Z-hydroxyethylamine, l-hydroxymethyl- 1-lower-aIkyl-Z-hydroxyethylamine or 1,1-bis(hydroxymethyl) -2-hydroxyethylamine.
- the compounds of Formula II are prepared by reacting the compounds of Formula I with formaldehyde.
- the reaction is preferably carried out by heating the formaldehyde and the 2-hydroxyethylamino-, l-hydroxymethyl-llower alkyl-Z-hydroxyethylaminoor 1,1-bis(hydroxymethyl) 2 hydroxyethylamino-lower-alkanoylaniline of Formula I at a temperature in the range from about 70 C. to about 150 C. in an organic solvent inert under the conditions of the reaction and with means for separating the water formed in the reaction.
- the water formed in the reaction is conveniently separated from the reaction by azeotropic distillation with the solvent used.
- Suitable solvents are water-immiscible solvents, for example benzene, toluene, xylene, and the like.
- a preferred solvent is benzene.
- the formaldehyde used can be in the form of an aqueous solution, such as Formalin, or in the form of a polymeric form of formaldehyde, such as trioxymethylene or paraformaldehyde. v
- the intermediate halo-lower-alkanoylanilines of Formula III are known compounds and are prepared by reacting an aniline with a slight molar excess of a halolower-alkanoyl halide.
- the reaction is preferably conducted in an organic solvent inert under the conditions of the reaction, for example benzene, toluene, xylene and the like, at a temperature in the range from about 70 C. to about C.
- the halo-lower-alkanoyl-N- lower-alkylanilines are prepared similarly by reacting a halo-lower-alkanoyl halide with an N-loWer-alkyl-su-bstituted-aniline.
- the latter in turn are prepared by reducing the corresponding N-lower-alkanoyl-substituted-anilines with an alkali metal aluminum hydride, for example, lithium aluminum hydride, in an organic solvent inert under the conditions of the reaction, for example, ether or tetrahydrofuran.
- an alkali metal aluminum hydride for example, lithium aluminum hydride
- the intermediate Z-hydroxyethylamines and l-hydroxymethyl-Z-hydroxyethylamines of Formula IV are prepared by reacting an appropriate nitroalkane with one or with two molar equivalents of formaldehyde, respectively, in the presence of a basic catalyst such as alkali metal carbonates, alkali metal hydroxides or alkali metal alkoxides and reducing the resulting Z-nitro-lower-alkanol or Z-nitro- 2-lower-alkyl-1,3-propanediol with hydrogen in the presence of a catalyst such as palladium-on-charcoal.
- the condensation of the nitroalkane with formaldehyde and the subsequent reduction of the resulting nitro-compound are preferably conducted in an organic solvent inert under the conditions of the reaction, for example methanol or ethanol.
- the novel compounds of the instant invention are the bases of Formulas I and II and the acid-addition salts of said bases.
- the compounds of the invention in free base form are converted to the acid-addition salt form by interaction of the base with an acid.
- the free bases can be regenerated from the acid-addition salt form in the conventional manner, that is, by treating the salts with strong aqueous bases, for example alkali metal hydroxides, alkali metal carbonates and alkali metal bicarbonates.
- the bases thus regenerated can then be interacted with the same or a different acid to give back the same or a different acid-addition salt.
- the novel bases and all of their acid-addition salts are readily inter-convertible.
- each of Formula I and Formula II not only represents the respective structural configuration of the bases of my invention but each is also representative of the respective structural entity which is common to all my respective compounds, whether in the form of the free bases or in the form of the acid-addition salts of the bases. I have found that by virtue of this common structural entity, the bases and their acid-addition salts have inherent pharmacodynamic activity of a type to be more fully described hereinbelow.
- This inherent pharmacodynamic activity can be enjoyed in useful form for pharmaceutical purposes by employing the free bases themselves or the acid-addition salts formed from pharmaceutically-acceptable acids, that is, acids whose anions are innocuous to the animal organism in effective doses of the salts so that beneficial properties inherent in the common structural entity represented by the free bases are not vitiated by side-effects ascribable to the anions.
- the waterinsoluble or toxic salts can be converted to the corresponding pharmaceutically-acceptable bases by decomposition of the salt with aqueous base as explained above, or alternatively, they can be converted to any desired pharmaceutically-acceptable acid-addition salt by double decomposition reactions involving the anion, for example, by ionexchange procedures.
- my salts are useful as characterizing or identifying derivatives of the free bases or in isolation or purification procedures.
- characterizing or purification salt derivatives can if desired be used to regenerate the pharmaceuticallyacceptable free bases by reaction of the salts with aqueous base, or alternatively can be converted to a pharmaceutically-acceptable acid-addition salt by, for example, ionexchange procedures.
- the novel feature of the compounds of the invention resides in the concept of the bases and cationic forms of the new 2-hydroxyethylamino-, l-hydroxymethyl-l-lower-alkyl-2-hydroxyethylamino, 1,1-bis(hydroxymethyl)-2- hydroxyethylamino-lower-alkanoylanilines and 3-oxazoli dinyl-lower-alkanoylanilines and not in any particular acid moiety or acid anion associated with the salt forms of my compounds; rather, the acid moieties or anions which can be associated in the salt forms are in themselves neither novel nor critical and therefore can be any acid anion or acid-like substance capable of salt formation with bases.
- the base form or water-soluble acid-addition salt form of the compounds of the invention both possess a common cation or ammonium ion.
- the acid-addition salts discussed above and claimed herein are prepared from any organic acid, inorganic acid (including organic acids having an inorganic group therein), or organometallic acid as exemplified by organic monoor polycarboxylic acids such as found, for example, in Beilsteins Organische Chemie, 4th ed., volumes III, IV, IX, X, XIV, XVII, XIX, XXI, XXII and XXV; organic monoand polysulfonic and -sulfinic acids such as found, for example in Beilstein, volumes VI, XI, XVI, and XXII; organic phosphonic and phosphinic acids such as found, for example, in Beilstein, volumes XI and XVI; organic acids of arsenic and antimony such as found, for example, in Beilstein, volume XVI; organic heterocyclic carboxylic sulfonic, and sulfinic acids such as found, for
- salt-forming compounds which are acidic in their chemical properties but which are not generally considered as acids in the same sense as carboxylic or sulfonic acids are also considered to be among the numerous acids which can be used to prepare acid-addition salts of the compounds of the invention.
- acidic phenolic compounds such as found, for example, in volume VI of Beilstein, acidic compounds having activated or acidic hydrogen atoms, as for example, picrolonic acid, or barbituric acid derivatives having an acidic proton such as found, for example, in Cox et al., Medicinal Chemistry, vol. IV, John Wiley and Sons, Inc., New York, NY. (1959).
- salt forming agents are socalled Lewis acids which lack a pair of electrons in the outer electron shell and react with basic compounds having an unshared pair of electrons to form salts, for example boron trifluoride.
- acid-addition salts are those derived from such diverse acids as formic acid, acetic acid, isobutyric acid, a-mercaptopropionic acid, malic acid, f umaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, l-naphthalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, Z-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, Z-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, 'benzenesulfonic acid, '
- the acid-addition salts are prepared either by dissolving the free base in an aqueous solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
- the compounds of my invention have pharmacodynamic properties, in particular, local anesthetic activity.
- Local anesthetic activity was determined according to the method of Bulbring and Wajda [J. Pharmacol. and Exptl. Therap. 85, 78 (1945 by injecting aqueous solutions of the acid-addition salts intradermally on the backs of guinea pigs using varying concentrations of solutions graded at 0.3 log intervals. The sensitivity of the wheals thereby produced was tested every five minutes for a period of thirty minutes by pricking the skins With a set of six pinpricks spaced at about one second intervals.
- the score for each wheal was obtained by the addition of the number of pinpricks which failed to elicit the reflex skin twitch at each reading.
- the average score for each concentration was plotted against the log of the concentration.
- the concentration expected to yield a score of 5, which was taken as the Threshold Activity Concentration (TAC) was estimated by extrapolation from the dose-response curves.
- the irritancies of the compounds were determined using the trypan blue irritation test procedure described by Hoppeet al; [1. Am. Pharm. Assoc., 39', 147 (1950)] as modified by Lu'duena and Hoppe [L Pharm. and Exptl. Therap., 104, 40 (1952)].
- each compound in a saline solution was injected at three or more concentrations graded at 0.3 log intervals into ten test areas per concentration.
- the average irritation score for each concentration was plotted against the dose on semilog paper and the value corresponding to a score of 4 was read from the graph. This value was called the Threshold Irritancy Concentration-4 (T and is taken to be the concentration expected to produce an average degree of irritation.
- the toxicities of the compounds were determined by intravenous injection in mice at various dose levels, and the LD the dose lethal to fifty percent of the animals at that dose level, was estimated.
- the compounds of my invention can be formulated in the manner conventional for local anesthetics.
- they can be conveniently used as their acid-addition salts, for example hydrochlorides, in aqueous liquid preparations.
- These preparations can be administered topically or injected intramuscularly or intravenously.
- they can be prepared for use as salves or creams for topical application by mixing with known adjuvants, for example, petroleum jelly.
- My compounds can also be advantageously combined with other pharmacologically active compounds, e.g. vasoconstrictor agents.
- the structures of the compounds of the invention are established by their mode of synthesis and corroborated by the correspondence between calculated values for the elements and values found by chemical analysis.
- Beta chlora-N-propionyl-N-methyl-2,6-dimethy[aniline [III; R R and R are CH R is H, Alk is CH CH Hal 1s Cl] was prepared by adding a solution of 15.22 g. (0.12 mole) of beta-chloropropionyl chloride in 60 m1. of dry benzene to a solution of 13.52 g. (0.10 mole) of N-methyl-2,6-dimethylaniline in 100 ml. of dry benzene and refluxing the mixture for one hour. The mixture was then washed with Water, the organic layer dried, the solvent removed in vacuo and the product purified by distillation in vacuo giving 17.1 g. of beta-chloro-N-propionyl-N-methyl-2, 6-dimethylaniline, B.P. 95103 C./ 0.14 mm., 115 1.5357.
- Beta-chloro N propionyl-N-ethyl-Z,6-dimethylaniline [III; R and R are CH R is H, R, is C H Alk is CH CH Hal is Cl] was prepared from 14.9 g. (0.10 mole) of N-ethy1-2,6-dimethylaniline in 100 ml. of dry benzene and 15.22 g. (0.12 mole) of beta-chloropropionyl chloride following the manipulative procedure described above in Example 5. The product was purified by distillation in vacuo giving 17.9 g. of beta-chloro-N-propionyl- N-ethyl-2,6-dimethylaniline, B.P. 100-102 C./0.1 mm., 12 1.5320.
- EXAMPLE 10 Alpha-bromo-N-propionyl N n pr0pyl-2,6-dimethylaniline [III; R and R are CH R is H, R; is I'l-C3H7, Alk is CHCI-I Hal is Br] was prepared from 16.3 g. (0.10 mole) of N-n-propyl-2,'6-dimethylaniline in 100 m1. of dry toluene and 25.9 g. (0.12 mole) of alpha-bromopropionyl bromide in 60 ml. of dry toluene following the manipulative procedure described above in Example 5. The product was recrystallized from hexane giving 18.0 g. of alpha-bromo-N-propionyl-N-n-propyl-2,6-dimethylaniline, M.P. 50.5-52 C. (uncorr.).
- EXAMPLE 14 1 -is0pr0pyl-1 -hydr0xymethyl-2-hydroxy ethylamine [IV; R is (CH CH, R is CH OH]
- EXAMPLE 16 1 -isobuly l-1 -hydroxymethyl-Z-hydr0xyethylamine
- R5 is iSQ-C4H9
- R6 is By following the manipulative procedure described above in Example 12, substituting for the 2-nitrobutane used therein a molar equivalent amount of 1-nitro-3- methylbutane and using two molar equivalent amounts of formaldehyde, there can be obtained l-isobutyl-l-hydroxymethyl-2-hydroxyethylamine.
- Alk is CH
- a solution of 19.8 g. (0.1 mole) of alpha-chloro-N- acetyl-Z,6-dimethylaniline and 26.7 g. (0.3 mole) of 1,1-dimethyl-2-hydroxyethylamine in 250 ml. of absolute ethanol was heated under reflux for forty-eight hours. The solvent was then removed under reduced pressure, the residual oil was mixed with 250 ml. of water, basified with potassium carbonate, and extracted with benzene. The benzene extracts were taken to dryness, the residue triturated with ether and the resulting solid collected by filtration.
- the crude product was recrystallized from an ethyl acetate-hexane mixture giving 15.6 g. of alpha-[(1, 1-dimethyl-2-hydroxyethyl amino] -N- acetyl-2,6-dimethylaniline, M.P. 85.287.0 C. (corr.).
- the irritancy of alpha-[(1,l-dimethyl-Z-hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline was determined using the trypan blue irritation test of Hoppe et al., ibid., and Luduena et al., ibid., described above.
- the Threshold Irritancy Concentration-4 (TIC for the compound was thus found to be 1.0%.
- LD Intravenous toxicity studies in mice with alpha-[(1,1- dimethyl 2 hydroxyethyDamino]-N-acetyl-2,6-dimethylaniline have shown the LD to be 941-54 mg./kg., Where LD is defined as the dose lethal to fifty percent of the animals at that dose level.
- Alpha- 1,1-dimethyl-Z-hydtoxyethyl) amino] -N-acetyl- 2,6-dimethylaniline reacts with formic acid, acetic acid, isobutyric acid, alpha-mercaptopropionic acid, malic acid, fumaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, l-naphthalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, 2-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, 2-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesul
- Alphal, 1-dimethyl-2-hydroxyethyl) amino] -N-acetyl- 2,6-dimethylaniline reacts with hydriodic acid to form alpha [(1,1 dimethyl-2-hydroxyethyl)amino]-N-acetyl- 2,6-dimethylaniline hydriodide, useful as a characterizing intermediate.
- Alpha- 1, l-dimethyl-Z-hydroxyethyl)amino] -N-acetyl- 2,6-dimethylaniline in the form of its hydriodide salt can be converted to the hydrochloride salt by passing an aqueous solution of the former over an ion-exchange resin saturated with chloride ions, for example, Rohm and Haas Amberlite IRA-400 resin.
- an ion-exchange resin saturated with chloride ions
- Amberlite IRA-400 resin for example, Rohm and Haas Amberlite IRA-400 resin.
- Alpha- 1, 1-dimethyl-2-hydroxyethyl) amino] -N-acetyl- 2,6-dimethylaniline can be converted to its hydriodide salt and the latter recrystallized for purification purposes from an appropriate organic solvent.
- hydriodide salt recrystallized for purification purposes from an appropriate organic solvent.
- alpha-[(1,1-dimethyl- 2-hydroxyethyl) amino] -N-acetyl-2,6-dimethylaniline can be recovered in purified free base form.
- Threshold Activity Concentration-5 TAC of alpha [(1 methyl 1 hydroxymethyI-Z-hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline determined according to the method of Bulbring and Wajda, ibid., was found to be 1.3%.
- Threshold Irritancy Concentration-4 (TIC of alpha-[ 1 methyl-1-hydroxymethyl-2-hydroxyethyl) amino] -N-acetyl-2,G-dimethylaniline determined according to the method of Hoppe et al., ibid., and Luduena et al., ibid., was found to be 4.0%
- mice with alpha-[(1- methyl-l-hydroxymethyl 2 hydroxyethyl)amino] N- acetyl-Z,6-dimethylaniline have shown the LD to be 138:8.0 mg./kg.
- CH R and R are H, R and R are CH OH, Alk is CH was prepared from 19.8 g. (0.1 mole) of alpha- 1 l chloro-N-acetyl-Z,6-dimethylaniline and 36.3 g. (0.3 mole) of 1,1-bis(hydroxymethyl)-2-hydroxyethylamine in 350 ml. of absolute ethanol following the manipulative procedure described above in Example 20. The product was recrystallized from ethanol giving 18.7 g. of alpha- ⁇ [l,1-bis(hydroxymethyl)-2-hydroxyethy1] amino ⁇ N- acetyl-2,6-dimethylaniline, M.P. l56.6159.4 C. (corr.).
- Threshold Activity Concentration-5 TAC of alpha- ⁇ [1,1-bis(hydroxymethyl) 2 hydroxyethyl1amino ⁇ -N-acetyl-2,6-dimethylaniline determined according to the method of Bulbring and Wajda, ibid., was found to 'be 2.0%.
- the Threshold Irritancy Concentration-4 (TIC of alpha- ⁇ [l,1-bis(hydroxymethyl) 2 hydroxyethyl]amino ⁇ -N-acetyl-2,6-dimethylaniline determined according to the method of Hoppe et al., ibid., and Luduena et al., ibid., was found to be 4.0%.
- mice with alpha- ⁇ [1,1- bis(hydroxymethyl)-2-hydroxyethyl]amino ⁇ N acetyl- 2,6-dimethylaniline have shown the LD to be 470:39 mg./kg.
- EXAMPLE 24 A lpha-[ (I -ethyl-1 -hydroxym ethyl-Z-hydroxyethyl amino -N -ethyl-N -pr-0pi0nyl-2-ch loro-6-methy lani line
- R1 is CH3,
- R2 is cl,
- R3 is H,
- R4 and R5 are C2H5,
- EXAMPLE 25 Gamma-[ (1-is0pr0pyl-1-hydroxymethyI-Z-hyaroxyethyl) amino] -N-n-pr0pyl-N-.butyry l-2-br0m-o-6-methylaniline
- a gamma-halo-N-npropyl-N-butyryl-Z-bromo 6 methylaniline and l-isopropyl-1-hydroxymethyl-2-hydroxyethylamine there can be obtained gamma-[(1-isopropyl-1-hydroxymethyl-2-hydroxyethyl)amino]-N-n-propyl-N-butyryl 2 bromo-6- methylaniline.
- R5 is lSO-C4H9, R is CH OH, lS
- EXAMPLE 28 Delta-[ (1 -methyI-1 -t-butyl-2-hydroxyethyl amino] -N-ethyl-N-valeryl-Z,6-dimethylaniline R R2 and R are CH3, R3 is H, R4 is C2H5, R5 is t-C4H9, is
- EXAMPLE 30 Epsilon [(I-n-pr0pyl-I-hydr0xymethyI-Z-hydroxyethyl) amino]-N n-butyl-N-aaproyl-4-n-but0xy-2,6-dimethylaniline
- R1 and R2 are CH3,
- R3 is 4-I1-C4H90,
- R4 is I'l-C4H9,
- R5 iS Il-C3H 1 R6 is CHZOH, is
- diethyl malonate By reacting 1,4-dibromobutane with one molar equivalent of diethyl malonate in the presence of an acid-acceptor, for example sodium ethoxide in an ethanol solvent, there can 'be obtained diethyl alpha-(4-bromobutyl) malonate.
- an acid-acceptor for example sodium ethoxide in an ethanol solvent
- diethyl alpha-(4-bromobutyl) malonate By heating the latter in aqueous alkali and isolating the product from an acid medium, there can be obtained epsilon bromocaproic acid.
- phosphorus tribromide By reacting the latter with phosphorus tribromide, there can be obtained epsilon bromocaproyl bromide.
- EXAMPLE 34 A lpha-[ (1,1-dimethyl-2-hydroxyethyl) amino] -N-acetyl- 2,6-dimcthyl-4-isopr0pylaniline R1, R2, R5 and R6 are CH3, R3 is 4*(CH3)2CH,
- R is H
- Alk is CH Alpha- (1,1 -dimethyl-2-hydr0xyethyl) amino] -N-nburyl-N-acetyl-2,3,6-trimethylaniline [1; R1, R2, R5 and R6 are CH3, R3 iS 3-CH3, R4 iS H-C4H9,
- Alk is CH
- alpha-chloro-N- acetyl-2,6-dimethylaniline used therein a molar equivalent amount of an alpha-halo-N-acetyl-2-isopropyl-6- methylaniline, there can be obtained alpha-[(1,1-dimethyl 2 hydroxyethyl)amino] N acetyl 2 isopropyl-6- methylaniline.
- R is H
- Alk is CH Alpha-(4,4-dimethyl-3-0xaz0lidirzyl) -N-acetyl-2,6- dimethylaniline [11; R R R and R are CH R and R, are H, Alk is CH
- a solution of 7.5 g. (0.03 mole) of alpha-[(1,1-dimethyl 2 hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline and 0.94 g. (0.032 mole) of paraformaldehyde in ml. of dry benzene was heated under reflux using a Dean-Stark trap for separation of the water formed in the reaction.
- Alpha (4 dimethyl 3 oxazolidinyl) N-acetyl-2,6- dimethylaniline reacts with formic acid, acetic acid, isobutyric acid, alpha-mercaptopropionic acid, malic acid, fumaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, 1- naththalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, Z-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, Z-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid,
- Alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl- 2,6-dimethylaniline reacts with hydriodic acid to form alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl 2, G-dimethylaniline hydriodide, useful as a characterizing intermediate.
- Alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl- 2,6-dimethylaniline in the form of its hydrodide salt can be converted to the hydrochloride salt by passing an aqueous solution of the former over an ion-exchange resin saturated with chloride ions, for example, Rohm and Haas Arnberlite IRA-400 resin.
- an ion-exchange resin saturated with chloride ions for example, Rohm and Haas Arnberlite IRA-400 resin.
- Alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl- 2,6-dimethylaniline can be converted to its hydriodide salt and the latter recrystallized for purification purposes from an appropriate organic solvent.
- hydriodide salt a compound that can be converted to its hydriodide salt and the latter recrystallized for purification purposes from an appropriate organic solvent.
- alpha-4,4-dimethyl- 3-0xazolidinyl)-N-acetyl-2,6-dimethylaniline can be recovered in purified free base form.
- R5 is CHZOH
- R5 is t-c H9
- EXAMPLE 49 Epsilon-(4-n-pr0pyl-4-hydroxymethyl-3-0mzolidinyl)- N -na-bwtyl-N-caproyll-n-butovcy-2,6-dfmethylwniline [11; R and R areCH R is 4-n-C H 0, R is n-C H R5 iS II'C3H7, R6 is CHzOH, is
- EXAMPLE 5 4 A lphal-(4,4-dimethyl-3-0xazolidinyl) -N-n-bmyl-N- acetyl-2,3,6-trimethylaniline R1, -R2, R5 and R6 are CH3, R3 is 3rCH3,
- R1 and R are C2H5, R3 4"CH3, R4 is H, R5 and R are CH3, is
- R3 is 4-CH3, R4 iS H, is
- R R and R are lower-alkyl of from one to four carbon atoms; and Alk represents lower-alkylene of from one to five carbon atoms.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
United States Patent 3,334,100 AMINO-LOWER-ALKANOYLANILINES Bernard L. Zenitz, Colonic, N.Y., assignor to Sterling Drug Inc., New York, N.Y., a corporation of Delaware No Drawing. Filed Apr. 22, 1960, Ser. No. 23,919 8 Claims. (Cl. 260-257) This invention relates to new 2-hydroxyethylaminolower alkanoylanilines, 3 oxazolidino-lower-alkanoylanilines, their acid-addition salts and to methods for the preparation thereof.
The 2-hydroxyethyl-tertiary amino-N-lower alkanoylanilines hitherto known have all lacked any further substitution on the l-carbon atom of the Z-hydroxyethyl group. The concept of the present invention resides in replacing the Z-hydroxyethyl-tertiary-amino group of such known compounds by a 1,1 di-lower-alkyl-Z-hydroxyethylsecondary-amino-, a l-lower-alkyl-l-hydroxymethyl-Z-hydroxyethyl-amino-, a 1,1-bis (hydroxymethyl)-2=hydroxy ethylaminoor a 3-oxazolidino group whereby new and useful compounds are obtained.
The compounds of the invention have the formula wherein R R and R each independently. represents hydrogen; lower-alkyl, lower-alkoxy or halogen radicals which can be the same or different; R represents hydrogen or lower-alkyl; R and R each independently represents lower-alkyl or the hydroxymethyl group; and Alk represents lower-alkylene.
When R R R R R and R represent lower-alkyl radicals or when R R and R represent lower-alkoxy radicals, they can have from one to about four carbon atoms and can be straight or branched and thus stand for such groups as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, and the like. When R R and R represent halogen atoms, they stand for any of the four halogens, fluorine, chlorine, bromine and iodine. A particularly preferred class of compounds are those in which R and R represent lower-alkyl radicals and R represents hydrogen.
In the above general Formulas I and II, Alk represents a lower-alkylene radical which contains from one to about five carbon atoms and can be either straight or branched. Thus the group CO-Alk includes such groups, inter alia, as
acetyl (COCH beta-propionyl (OOCH CH alpha-propionyl (COCHCH gamma-butyryl (COCHgCH CH alpha-methyl-beta-propionyl (COCHCH CH beta-butyryl (COCH CHCH delta-valeryl (COCH CH CH CH alpha-methyl-gamma-butyryl (COCHCH CH CH epsilon-caproyl (cOcH CH CH CH Cl-l and the like.
The compounds of Formula I are prepared by reacting ice a halo-lower-alkanoylaniline with a Z-hydroxyethylamine (R and R are lower-alkyl), a l-hydroxymethyl-l-loweralkyl-2-hydroxyethylamine (R is lower-alkyl; R is hydroxymethyl), or a 1,1-bis-(hydroxymethyl)-2-hydroxyethylamine (R and R are hydroxymethyl) as illustrated by the equation given below where R R R R R R and Alk have the meanings given above and Hal represents halogen.
a I lia Q-n-OO-Am-Hn HZN IJGH2OH R4 R5 R2 III IV R1 Ra 5 Q-n-oo-mannpomon R4 Re R:
A preferred method comprises heating a 2-hydroxyethylamine, 1 hydroxymethyl-1-lower-alkyl-2-hydroxyethylamine or 1,1 bis(hydroxymethyl)-2-hydroxyethylamine with a halo-lower-alkanoylaniline at a temperature in the range from about 50 C. to 150 C. in the presence of an acid-acceptor. The reaction is preferably carried out in an organic solvent, inert under the conditions of the reaction, for example methanol, ethanol, propanol, acetonitrile, benzene, xylene and the like. The purpose of the acid-acceptor is to take up the hydrogen halide which is split out during the course of the reaction. The acid-acceptor is a basic substance which forms watersoluble by-products easily separable from the main product of the reaction, and includes such substances as alkali metal salts of weak acids, i.e. sodium carbonate, potassium carbonate, sodium acetate or sodium alkoxides. The acid-acceptor can also be in the form of an excess quantity of the Z-hydroxyethylamine, l-hydroxymethyl- 1-lower-aIkyl-Z-hydroxyethylamine or 1,1-bis(hydroxymethyl) -2-hydroxyethylamine.
The compounds of Formula II are prepared by reacting the compounds of Formula I with formaldehyde. The reaction is preferably carried out by heating the formaldehyde and the 2-hydroxyethylamino-, l-hydroxymethyl-llower alkyl-Z-hydroxyethylaminoor 1,1-bis(hydroxymethyl) 2 hydroxyethylamino-lower-alkanoylaniline of Formula I at a temperature in the range from about 70 C. to about 150 C. in an organic solvent inert under the conditions of the reaction and with means for separating the water formed in the reaction. The water formed in the reaction is conveniently separated from the reaction by azeotropic distillation with the solvent used. Suitable solvents are water-immiscible solvents, for example benzene, toluene, xylene, and the like. A preferred solvent is benzene. The formaldehyde used can be in the form of an aqueous solution, such as Formalin, or in the form of a polymeric form of formaldehyde, such as trioxymethylene or paraformaldehyde. v
The intermediate halo-lower-alkanoylanilines of Formula III are known compounds and are prepared by reacting an aniline with a slight molar excess of a halolower-alkanoyl halide. The reaction is preferably conducted in an organic solvent inert under the conditions of the reaction, for example benzene, toluene, xylene and the like, at a temperature in the range from about 70 C. to about C. The halo-lower-alkanoyl-N- lower-alkylanilines are prepared similarly by reacting a halo-lower-alkanoyl halide with an N-loWer-alkyl-su-bstituted-aniline. The latter in turn are prepared by reducing the corresponding N-lower-alkanoyl-substituted-anilines with an alkali metal aluminum hydride, for example, lithium aluminum hydride, in an organic solvent inert under the conditions of the reaction, for example, ether or tetrahydrofuran.
The intermediate Z-hydroxyethylamines and l-hydroxymethyl-Z-hydroxyethylamines of Formula IV (R is loweralkyl or hydroxymethyl, R is lower-alkyl) are prepared by reacting an appropriate nitroalkane with one or with two molar equivalents of formaldehyde, respectively, in the presence of a basic catalyst such as alkali metal carbonates, alkali metal hydroxides or alkali metal alkoxides and reducing the resulting Z-nitro-lower-alkanol or Z-nitro- 2-lower-alkyl-1,3-propanediol with hydrogen in the presence of a catalyst such as palladium-on-charcoal. The condensation of the nitroalkane with formaldehyde and the subsequent reduction of the resulting nitro-compound are preferably conducted in an organic solvent inert under the conditions of the reaction, for example methanol or ethanol.
The novel compounds of the instant invention are the bases of Formulas I and II and the acid-addition salts of said bases. The compounds of the invention in free base form are converted to the acid-addition salt form by interaction of the base with an acid. In like manner, the free bases can be regenerated from the acid-addition salt form in the conventional manner, that is, by treating the salts with strong aqueous bases, for example alkali metal hydroxides, alkali metal carbonates and alkali metal bicarbonates. The bases thus regenerated can then be interacted with the same or a different acid to give back the same or a different acid-addition salt. Thus the novel bases and all of their acid-addition salts are readily inter-convertible.
It will thus be appreciated that each of Formula I and Formula II not only represents the respective structural configuration of the bases of my invention but each is also representative of the respective structural entity which is common to all my respective compounds, whether in the form of the free bases or in the form of the acid-addition salts of the bases. I have found that by virtue of this common structural entity, the bases and their acid-addition salts have inherent pharmacodynamic activity of a type to be more fully described hereinbelow. This inherent pharmacodynamic activity can be enjoyed in useful form for pharmaceutical purposes by employing the free bases themselves or the acid-addition salts formed from pharmaceutically-acceptable acids, that is, acids whose anions are innocuous to the animal organism in effective doses of the salts so that beneficial properties inherent in the common structural entity represented by the free bases are not vitiated by side-effects ascribable to the anions.
In utilizing this pharmacodynamic activity of the salts of the invention, I prefer of course to use pharmaceutically-acceptable salts. Although water-insolubility, high toxicity, or lack of crystalline character may make some particular salt species unsuitable or less desirable for use as such in a given pharmaceutical application, the waterinsoluble or toxic salts can be converted to the corresponding pharmaceutically-acceptable bases by decomposition of the salt with aqueous base as explained above, or alternatively, they can be converted to any desired pharmaceutically-acceptable acid-addition salt by double decomposition reactions involving the anion, for example, by ionexchange procedures.
Moreover, apart from their usefulness in pharmaceutical applications, my salts are useful as characterizing or identifying derivatives of the free bases or in isolation or purification procedures. Like all of the acid-addition salts, such characterizing or purification salt derivatives can if desired be used to regenerate the pharmaceuticallyacceptable free bases by reaction of the salts with aqueous base, or alternatively can be converted to a pharmaceutically-acceptable acid-addition salt by, for example, ionexchange procedures.
It will be appreciated from the foregoing that all of the acid-addition salts of my new bases are useful and valuable compounds, regardless of considerations of solubility, toxicity, physical form, and the like, and are accordingly within the purview of the instant invention.
The novel feature of the compounds of the invention, then, resides in the concept of the bases and cationic forms of the new 2-hydroxyethylamino-, l-hydroxymethyl-l-lower-alkyl-2-hydroxyethylamino, 1,1-bis(hydroxymethyl)-2- hydroxyethylamino-lower-alkanoylanilines and 3-oxazoli dinyl-lower-alkanoylanilines and not in any particular acid moiety or acid anion associated with the salt forms of my compounds; rather, the acid moieties or anions which can be associated in the salt forms are in themselves neither novel nor critical and therefore can be any acid anion or acid-like substance capable of salt formation with bases. In fact, in aqueous solutions, the base form or water-soluble acid-addition salt form of the compounds of the invention both possess a common cation or ammonium ion.
Thus the acid-addition salts discussed above and claimed herein are prepared from any organic acid, inorganic acid (including organic acids having an inorganic group therein), or organometallic acid as exemplified by organic monoor polycarboxylic acids such as found, for example, in Beilsteins Organische Chemie, 4th ed., volumes III, IV, IX, X, XIV, XVII, XIX, XXI, XXII and XXV; organic monoand polysulfonic and -sulfinic acids such as found, for example in Beilstein, volumes VI, XI, XVI, and XXII; organic phosphonic and phosphinic acids such as found, for example, in Beilstein, volumes XI and XVI; organic acids of arsenic and antimony such as found, for example, in Beilstein, volume XVI; organic heterocyclic carboxylic sulfonic, and sulfinic acids such as found, for example, in Beilstein, volumes XVIII, XXII, and XXV; acidic ion exchange resins, and inorganic acids of any acid forming element or combination of elements such as found in Mellor, Comprehensive Treatise on Inorganic and Theoretical Chemistry, Longmans, Green and Co., New York, N.Y., volumes IXVI. In addition, other salt-forming compounds which are acidic in their chemical properties but which are not generally considered as acids in the same sense as carboxylic or sulfonic acids are also considered to be among the numerous acids which can be used to prepare acid-addition salts of the compounds of the invention. Thus there is also comprehended acidic phenolic compounds such as found, for example, in volume VI of Beilstein, acidic compounds having activated or acidic hydrogen atoms, as for example, picrolonic acid, or barbituric acid derivatives having an acidic proton such as found, for example, in Cox et al., Medicinal Chemistry, vol. IV, John Wiley and Sons, Inc., New York, NY. (1959). Also comprehended as salt forming agents are socalled Lewis acids which lack a pair of electrons in the outer electron shell and react with basic compounds having an unshared pair of electrons to form salts, for example boron trifluoride.
Thus appropriate acid-addition salts are those derived from such diverse acids as formic acid, acetic acid, isobutyric acid, a-mercaptopropionic acid, malic acid, f umaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, l-naphthalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, Z-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, Z-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, 'benzenesulfonic acid, p-toluenesulfonic acid, benzenesulfinic acid, butylarsonic acid, diethylphosphinic acid, p-aminophenylarsinic acid, phenylstibnic acid, phenylphosphinous acid, methylphosphonic acid, phenylphosphinic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, perchloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrocyanic acid, phosphotungstic acid, molybdic acid, phosphomolybdic acid, pyrophosphoric acid, arsenic acid, picric acid, picolonic acid, barbituric acid, boron trifluoride, and the like.
The acid-addition salts are prepared either by dissolving the free base in an aqueous solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
The compounds of my invention have pharmacodynamic properties, in particular, local anesthetic activity. Local anesthetic activity was determined according to the method of Bulbring and Wajda [J. Pharmacol. and Exptl. Therap. 85, 78 (1945 by injecting aqueous solutions of the acid-addition salts intradermally on the backs of guinea pigs using varying concentrations of solutions graded at 0.3 log intervals. The sensitivity of the wheals thereby produced was tested every five minutes for a period of thirty minutes by pricking the skins With a set of six pinpricks spaced at about one second intervals. The score for each wheal was obtained by the addition of the number of pinpricks which failed to elicit the reflex skin twitch at each reading. The average score for each concentration was plotted against the log of the concentration. The concentration expected to yield a score of 5, which was taken as the Threshold Activity Concentration (TAC was estimated by extrapolation from the dose-response curves.
The irritancies of the compounds were determined using the trypan blue irritation test procedure described by Hoppeet al; [1. Am. Pharm. Assoc., 39', 147 (1950)] as modified by Lu'duena and Hoppe [L Pharm. and Exptl. Therap., 104, 40 (1952)]. In the test, each compound in a saline solution was injected at three or more concentrations graded at 0.3 log intervals into ten test areas per concentration. The average irritation score for each concentration was plotted against the dose on semilog paper and the value corresponding to a score of 4 was read from the graph. This value was called the Threshold Irritancy Concentration-4 (T and is taken to be the concentration expected to produce an average degree of irritation.
The toxicities of the compounds were determined by intravenous injection in mice at various dose levels, and the LD the dose lethal to fifty percent of the animals at that dose level, was estimated.
The compounds of my invention can be formulated in the manner conventional for local anesthetics. For example, they can be conveniently used as their acid-addition salts, for example hydrochlorides, in aqueous liquid preparations. These preparations can be administered topically or injected intramuscularly or intravenously. Alternatively they can be prepared for use as salves or creams for topical application by mixing with known adjuvants, for example, petroleum jelly. My compounds can also be advantageously combined with other pharmacologically active compounds, e.g. vasoconstrictor agents.
The structures of the compounds of the invention are established by their mode of synthesis and corroborated by the correspondence between calculated values for the elements and values found by chemical analysis.
Preparation :of intermediates EXAMPLE 1 N-methyl-Z, 6-dimethylaniline To a stirred mixture of 19 g. (0.50 mole) of lithium aluminum hydride in 200 ml. of dry tetrahydrofuran, there was added over a period of about one hour a slurry of 37.3 g. (0.25 mole) of N-formyl-2,6-xylidine in 800 ml. of tetrahydrofuran. The mixture was heated under reflux for about eighteen hours, cooled to about and the excess lithium aluminum hydride decomposed by dropwise addition of 40 ml. of water in 40 ml. of tetrahydrofuran. The mixture was filtered, the filter cake washed with about 200 ml. of tetrahydrofuran, and the filtrate was taken to dryness under reduced pressure. The oily residue was distilled to 29 mm. Hg and the fraction boiling at 100104.5 C. was collected as product. There was thus obtained 26.5 g. of N-methyl-2,6- dimethylaniline.
Analysl's.-Calcd. for C H N: N, 10.35. Found: N, 10.22.
EXAMPLE 2 N-ethyl-2,6-dim'ethylaniline was prepared from 40.8
g. (0.25 mole) of N-acetyl-2,6-xylidine in 650 ml. of dry tetrahydrofiiran and 19.0 g. (0.50 mole) of lithium aluminum hydride in 150 ml. of dry tetrahydrofuran following the manipulative procedure described above in Example 1. The product was collected at 93-95 C./15 mm. giving 10.1 g. of N-ethyl-Z,6-dimethylaniline; n 1.5225.
Analysis.Calcd. for C H N: N, 9:38. Found: N, 9.29.
EXAMPLE 3 A lpha-chloro-N-acezyl-N-methyl-Z,6-dimethylaniline [1111; R R and R are CH R is H, Alk is CH Hal is Cl.]
In a beaker cooled in an ice bath and equipped with a mechanical stirrer and a thermometer, 24.1 g. (0.20 mole) of N-methyl-2,G-dimethylaniline was dissolved in 158 ml. of glacial acetic acid. The temperature of the solution was lowered to about 10 C., and 22.8 g. (0.20 mole) of chloroacetyl chloride was added all at once with stirring. A chilled solution of 61.3 g. (0.88 mole) of sodium acetate in 250 ml. of water was added portionw1se at about 10-15 C. The solution was stirred for one hour in an ice bath and then diluted with about 2.5 liters of water. The solid which separated was filtered, air-dried and recrystallized from an ethanol-water mixture giving 9.2 g. of alpha-chloro-N-acetyl-N-methyl-2,6-dimethylaniline, M.P. 59.5-61 C. (uncorr.).
Analysis.Calcd. for C H ClNO: N, 6.63; Cl, 16.77 Found: N, 6.39; Cl, 16.90.
EXAMPLE 5 Beta chlora-N-propionyl-N-methyl-2,6-dimethy[aniline [III; R R and R are CH R is H, Alk is CH CH Hal 1s Cl] was prepared by adding a solution of 15.22 g. (0.12 mole) of beta-chloropropionyl chloride in 60 m1. of dry benzene to a solution of 13.52 g. (0.10 mole) of N-methyl-2,6-dimethylaniline in 100 ml. of dry benzene and refluxing the mixture for one hour. The mixture was then washed with Water, the organic layer dried, the solvent removed in vacuo and the product purified by distillation in vacuo giving 17.1 g. of beta-chloro-N-propionyl-N-methyl-2, 6-dimethylaniline, B.P. 95103 C./ 0.14 mm., 115 1.5357.
Analysis.Calcd. for C H CINO: C, 63.82; H, 7.14; N, 6.20. Found: C, 63.83; H, 7.08; N, 6.30.
EXAMPLE 6 Alpha-bromo N propionyl-N-methyl-2,6-dimethylaniline [III; R R and R are CH R is H, Alk is CHCH Hal is Br] was prepared from 13.5 g. (0.1 mole) of N-methyl 2,6-dimethylaniline in ml. of dry benzene and 25.9 g. (0.12 mole) of alpha-bromopropionyl bromide following the manipulative procedure described above in Example 5. The product was recrystallized from hexane giving 17.1 g. of alpha-hromo-N-propionyl-N- methyl-2,6-dimethylaniline, M.P. 8081.5 C. (uncorr.).
Analysis.Calcd. for C H BrNO: C, 53.34; H, 5.97; Br, 29. 6. Found: C, 53.29; H, 5.77; Br, 29.4.
EXAMPLE 7 Alpha-chlora N acetyl-N-ethyl-2,6-dimethylaniline [III; R and R are CH R is H, R; is C H Alk is CH Hal is Cl] was prepared from 9.6 g. (0.64 mole) of N-ethyl-2,6-dimethylaniline in 60 ml. of dry toluene and 15 ml. of chloroacetyl chloride following the manipulative procedure described above in Example 5. The product was recrystallized from pentane giving 10.8 g. of alpha-chloro N acetyl-N-ethyl-2,6-dirnethylaniline, M.P. 41-43" C. (uncorr.).
Analysis.-Calcd. for C H ClNO: C, 63.82; H, 7.14; N, 6.20. Found: C, 63.97; H, 7.05; N, 6.23.
EXAMPLE 8 Beta-chloro N propionyl-N-ethyl-Z,6-dimethylaniline [III; R and R are CH R is H, R, is C H Alk is CH CH Hal is Cl] was prepared from 14.9 g. (0.10 mole) of N-ethy1-2,6-dimethylaniline in 100 ml. of dry benzene and 15.22 g. (0.12 mole) of beta-chloropropionyl chloride following the manipulative procedure described above in Example 5. The product was purified by distillation in vacuo giving 17.9 g. of beta-chloro-N-propionyl- N-ethyl-2,6-dimethylaniline, B.P. 100-102 C./0.1 mm., 12 1.5320.
Analysis.Calcd. for C H ClNO: N, 5.84; Cl, 14.80. Found: N, 5.94; CI, 15.00.
EXAMPLE 9 Alpha chloro N acetyl-N-n-propyl-2,6-dimefhylaniline [III; R and R are CH R is H, R, is n-C3H7, Alk is CH Hal is Cl] was prepared from 16.3 g. (0.1 mole) of N-n-propyl-2,6-dimethylaniline in 150 m1. of dry benzene and 15.0 g. (0.13 mole) of chloroacetyl chloride in 60 ml. of dry benzene following the manipulative procedure described above in Example 5. The product was recrystallized from hexane giving 20.1 g. of alpha-chloro- N-acetyl-N-n-propyl-2,6-dimethy1aniline, M.P. 5960 C. (uncorr.).
Analysis.-Calcd. for C H ClNO: N, 5.84; Cl, 14.80. Found: N, 5.92; Cl, 15.00.
EXAMPLE 10 EXAMPLE 11 Alpha-bromo-N-propionyl N n pr0pyl-2,6-dimethylaniline [III; R and R are CH R is H, R; is I'l-C3H7, Alk is CHCI-I Hal is Br] was prepared from 16.3 g. (0.10 mole) of N-n-propyl-2,'6-dimethylaniline in 100 m1. of dry toluene and 25.9 g. (0.12 mole) of alpha-bromopropionyl bromide in 60 ml. of dry toluene following the manipulative procedure described above in Example 5. The product was recrystallized from hexane giving 18.0 g. of alpha-bromo-N-propionyl-N-n-propyl-2,6-dimethylaniline, M.P. 50.5-52 C. (uncorr.).
Analysis.Calcd. for C H BrNO: C, 56.45; H, 6.76; Br, 26.8. Found: C, 56.03; H, 6.52; Br, 26.8.
8 EXAMPLE 12 1-m'ethyl-1-ethyl-2-hydr0xyethylamine [IV; R is CH R is CH CH By reacting 2-nitrobutane with one molar equivalent of formaldehyde in a methanol solution in the presence of sodium methoxide, there can be obtained 2-methyl-2- nitrobutanol which, on catalytic reduction with hydrogen over a palladium-on-charcoal catalyst in an inert organic solvent, for example ethanol, gives l-methyl-l-ethyl-Z- hydroxyethylamine.
EXAMPLE 13 1-ethyl-1-hydr0xymethyI-Z-hydroxyethylamine R5 is C2H5, R5 is By following the manipulative procedure described above in Example 12, substituting for the 2-nitrobutane used therein a molar equivalent amount of l-nitropropane and using two molar equivalents of formaldehyde, there can be obtained l-ethyl-1-hydroxymethyl-2-hydroxyethylamine.
EXAMPLE 14 1 -is0pr0pyl-1 -hydr0xymethyl-2-hydroxy ethylamine [IV; R is (CH CH, R is CH OH] By following the manipulative procedure described above in Example 12, substituting for the Z-nitrobutane used therein a molar equivalent amount of l-nitro-2- methylpropane and using two molar equivalents for formaldehyde, there can be obtained l-isopropyl-l-hydroxymethyl-2-hydroxyethylamine.
EXAMPLE 15 1,1-diethyl-Z-hydroxyelhylamine [IV; R and R are C H By following the manipulative procedure described above in Example 12, substituting for the Z-nitrobutane used therein a molar equivalent amount of 3-nitropentane, there can be obtained 1,1-diethyl-2-hydroxyethylamine.
EXAMPLE 16 1 -isobuly l-1 -hydroxymethyl-Z-hydr0xyethylamine R5 is iSQ-C4H9, R6 is By following the manipulative procedure described above in Example 12, substituting for the 2-nitrobutane used therein a molar equivalent amount of 1-nitro-3- methylbutane and using two molar equivalent amounts of formaldehyde, there can be obtained l-isobutyl-l-hydroxymethyl-2-hydroxyethylamine.
EXAMPLE l7 1-t-bmyl-1-methyl-2-hydr0xyethy[amine R5 is t-C4H9, R6 is By following the manipulative procedure described above in Example 12, substituting for the 2-nitrobutane used therein a molar equivalent amount of 2-nitro-3,3-
dimethylbutane, there can be obtained l-t-butyl-l-methyl- 2-hydroxyethylamine.
EXAMPLE 18 1-is0butyl-1-is0pr0pyl-2-hydroxyethylamine R5 iS (CH3)2CH, R6 is iSO'C4H9] By following the manipulative procedure described above in Example 12, substituting for the 2-nitr0butane used therein a molar equivalent amount of 3-nitro-2,5- dimethylhexane, there can be obtained l-isobutyl-l-isopropyl-2-hydroxyethylamine.
9 EXAMPLE 19 1-n-pr0pyl-1-hydr0xymethyI-Z-hydroucyethylamine R iS H-CgHq, R6 is By following the manipulative procedure described above in Example 12, substituting for the 2-nitrobutane used therein a molar equivalent amount of l-nitrobutane and using two molar equivalent amounts of formaldehyde, there can be obtained l-n-propyl-l-hydroxymethyl- 2-hydroxyethylamine.
Preparation of final products EXAMPLE 20 Alpha-[ (1,1-dimethyl-2-hydr0xyethyl)amino]-N-acetyl- 2,6-dimethylan iline R1, R2, R5 and R are CH3, R3 and R4 are H,
Alk is CH A solution of 19.8 g. (0.1 mole) of alpha-chloro-N- acetyl-Z,6-dimethylaniline and 26.7 g. (0.3 mole) of 1,1-dimethyl-2-hydroxyethylamine in 250 ml. of absolute ethanol was heated under reflux for forty-eight hours. The solvent was then removed under reduced pressure, the residual oil was mixed with 250 ml. of water, basified with potassium carbonate, and extracted with benzene. The benzene extracts were taken to dryness, the residue triturated with ether and the resulting solid collected by filtration. The crude product Was recrystallized from an ethyl acetate-hexane mixture giving 15.6 g. of alpha-[(1, 1-dimethyl-2-hydroxyethyl amino] -N- acetyl-2,6-dimethylaniline, M.P. 85.287.0 C. (corr.).
Analysis.-Calcd. for CHI-123N202: N t N 5.60. Found: N t N 5.53.
Pharmacological evaluation of alpha-[(1,1-dimethyl-2- hydroxyethyl)amino] N acetyl-2,6-dimethylaniline in aqueous solution in the form of its acid-addition salts administered intradermally in guinea pigs according to the method of Bulbring and Wajda, ibid., described above, has shown that the compound possesses local anesthetic 7 activity. The Threshold Activity Concentration-5 (TAC for the compound was thus found to be 0.33%
The irritancy of alpha-[(1,l-dimethyl-Z-hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline was determined using the trypan blue irritation test of Hoppe et al., ibid., and Luduena et al., ibid., described above. The Threshold Irritancy Concentration-4 (TIC for the compound was thus found to be 1.0%.
Intravenous toxicity studies in mice with alpha-[(1,1- dimethyl 2 hydroxyethyDamino]-N-acetyl-2,6-dimethylaniline have shown the LD to be 941-54 mg./kg., Where LD is defined as the dose lethal to fifty percent of the animals at that dose level.
Alpha- 1,1-dimethyl-Z-hydtoxyethyl) amino] -N-acetyl- 2,6-dimethylaniline reacts with formic acid, acetic acid, isobutyric acid, alpha-mercaptopropionic acid, malic acid, fumaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, l-naphthalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, 2-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, 2-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, p-toluenesulfonic acid, benzenesulfinic acid, butylarsonic acid, diethylphosphinic acid, p-aminophenylarsinic acid, phenylstibnic acid, phenylphosphinous acid, methylphosphonic acid, phenylphosphinic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, perchloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrocyanic acid, phosphotungstic acid, molybdic acid, phosphomolybdic acid, pyrophosphoric acid, arsenic acid, picric acid, picrolonic acid, barbituric acid, boron trifluoride, and the like, to give, respectively, the formate,
cholate, pyrenecarboxylate, 2-pyridinecarboxylate, 3-indoleacetate, quinate, sulfamate, methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate, benzenesulfinate, butylarsonate, diethylphosphinate, p-aminophenylarsinate, phenylstibnate, phenylphosphinite, methylphosphonate, phenylphosphinate, hydrofluoride, hydrochloride, hydrobromide, hydriodide, perchlorate, nitrate, sulfate (or bisulfate), phosphate (or acid phosphate), hydrocyanide, phosphotungstate, molybdate, phosphomolybdate, pyrophosphate, arsenate, picrate, picrolonate, barbiturate and boron trifluoride salts.
Alphal, 1-dimethyl-2-hydroxyethyl) amino] -N-acetyl- 2,6-dimethylaniline reacts with hydriodic acid to form alpha [(1,1 dimethyl-2-hydroxyethyl)amino]-N-acetyl- 2,6-dimethylaniline hydriodide, useful as a characterizing intermediate.
Alpha- 1, l-dimethyl-Z-hydroxyethyl)amino] -N-acetyl- 2,6-dimethylaniline in the form of its hydriodide salt can be converted to the hydrochloride salt by passing an aqueous solution of the former over an ion-exchange resin saturated with chloride ions, for example, Rohm and Haas Amberlite IRA-400 resin.
Alpha- 1, 1-dimethyl-2-hydroxyethyl) amino] -N-acetyl- 2,6-dimethylaniline can be converted to its hydriodide salt and the latter recrystallized for purification purposes from an appropriate organic solvent. On suspension of the hydriodide in dilute aqueous sodium hydroxide, extraction of the suspension with chloroform, and removal of the chloroform from the extracts, alpha-[(1,1-dimethyl- 2-hydroxyethyl) amino] -N-acetyl-2,6-dimethylaniline can be recovered in purified free base form.
EXAMPLE 21 Alpha [(1 methyl-I-hydroxymethyl-Z-hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline [I; R R and R are CH3, R3 and R4 are H, R6 is CHzOH, is was prepared from 19.8 g. (0.1 mole) of alpha-chloro- N-acetyl-Z,6-dimethylaniline and 31.5 g. (0.3 mole) of l-methyl-1-hydroxymethyl-2-hydroxyethylamine in 350 ml. of absolute ethanol following the manipulative procedure described above in Example 20. The product was recrystallized from ethyl acetate giving 16 g. of alpha- 1 methyl 1 hydroxymethyl-2-hydroxyethyl)amino]- N-acetyl-Z,G-dimethylaniline, M.P. 102.2-104.2 C. (corr.).
Analysis.-Calcd. for C H N O N 10.52; N Found: N'r t N i The Threshold Activity Concentration-5 (TAC of alpha [(1 methyl 1 hydroxymethyI-Z-hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline determined according to the method of Bulbring and Wajda, ibid., was found to be 1.3%.
The Threshold Irritancy Concentration-4 (TIC of alpha-[ 1 methyl-1-hydroxymethyl-2-hydroxyethyl) amino] -N-acetyl-2,G-dimethylaniline determined according to the method of Hoppe et al., ibid., and Luduena et al., ibid., was found to be 4.0%
Intravenous toxicity studies in mice with alpha-[(1- methyl-l-hydroxymethyl 2 hydroxyethyl)amino] N- acetyl-Z,6-dimethylaniline have shown the LD to be 138:8.0 mg./kg.
CH R and R are H, R and R are CH OH, Alk is CH was prepared from 19.8 g. (0.1 mole) of alpha- 1 l chloro-N-acetyl-Z,6-dimethylaniline and 36.3 g. (0.3 mole) of 1,1-bis(hydroxymethyl)-2-hydroxyethylamine in 350 ml. of absolute ethanol following the manipulative procedure described above in Example 20. The product was recrystallized from ethanol giving 18.7 g. of alpha- {[l,1-bis(hydroxymethyl)-2-hydroxyethy1] amino} N- acetyl-2,6-dimethylaniline, M.P. l56.6159.4 C. (corr.).
Analysis.Calcd. for C H N O N 9.93; N' Found: N t l, Ng l The Threshold Activity Concentration-5 (TAC of alpha-{[1,1-bis(hydroxymethyl) 2 hydroxyethyl1amino}-N-acetyl-2,6-dimethylaniline determined according to the method of Bulbring and Wajda, ibid., was found to 'be 2.0%.
The Threshold Irritancy Concentration-4 (TIC of alpha-{[l,1-bis(hydroxymethyl) 2 hydroxyethyl]amino}-N-acetyl-2,6-dimethylaniline determined according to the method of Hoppe et al., ibid., and Luduena et al., ibid., was found to be 4.0%.
Intravenous toxicity studies in mice with alpha-{[1,1- bis(hydroxymethyl)-2-hydroxyethyl]amino} N acetyl- 2,6-dimethylaniline have shown the LD to be 470:39 mg./kg.
EXAMPLE 23 Beta- (1-methyl-I-ethyl-2-hydr0xyethyl) amino] -N-ispropyl-N-pro iionylaniIine R1, R2 and R3 are H, R4 is (CH3)2CH, R is CH3,
R is CH CH Alk is CH CH By following the manipulative procedure described above in Example 20, substituting for the reactants used therein molar equivalent amounts of a beta-halo-N-isopropyl-N-propionylaniline and l-methyl-l-ethyl 2 hydroxyethylamine, there can be obtained beta-[(l-methyl- 1-ethyl-2-hydroxyethyl)amino]-N-isopropyl N propionylaniline.
EXAMPLE 24 A lpha-[ (I -ethyl-1 -hydroxym ethyl-Z-hydroxyethyl amino -N -ethyl-N -pr-0pi0nyl-2-ch loro-6-methy lani line R1 is CH3, R2 is cl, R3 is H, R4 and R5 are C2H5, R5
is CHzOH, Alk is CHCH By following the manipulative procedure described above in Example 20, substituting for the reactants used therein a molar equivalent amount of an alpha-halo-N- ethyl-N-propionyl 2-chloro-6-methylaniline and l-ethyll-hydroxymethyl-2-hydroxyethylamine, there can be obtained alpha-[ l-ethyl-1-hydroxymethyl-2-hydroxyethyl) amino] -N-ethyl-N-propionyl-2-chloro-6-methylaniline.
EXAMPLE 25 Gamma-[ (1-is0pr0pyl-1-hydroxymethyI-Z-hyaroxyethyl) amino] -N-n-pr0pyl-N-.butyry l-2-br0m-o-6-methylaniline By following the manipulative procedure described above in Example 20, substituting for the reactants used therein molar equivalent amounts of a gamma-halo-N-npropyl-N-butyryl-Z-bromo 6 methylaniline and l-isopropyl-1-hydroxymethyl-2-hydroxyethylamine, there can be obtained gamma-[(1-isopropyl-1-hydroxymethyl-2-hydroxyethyl)amino]-N-n-propyl-N-butyryl 2 bromo-6- methylaniline.
EXAMPLE 26 A lpha-methyl-beta[ (1,1-diethyl-2-hydn0xyethyl)amino] N -methy l-N -pr0pi 0nyl-2,6 -dimethy lani line [1; R R and R are CH R is H, R and R are C H Alk is CH(CH )CH By following the manipulative procedure described above in Example 20, substituting for the reactants used therein molar equivalent amounts of an alpha-methylbeta-halo-N-methyl-N-propionyl-2,G-dimethylaniline and 1,l-diethyl-2-hydroxyethylamine, there can be obtained alpha-methyl-beta-[(l,l diethyl 2 hydroxyethyl)amino] -N-methyl-N-propionyl-2,6-dimethylaniline.
EXAMPLE 27 Beta- (1-is0butyl-1-hydroxymelhyZ-Z-hydroxyethyl) amino] -N-b utyry l-2,4,6-triis0pr0py laniline 1; R and R2 are (CH3)2CH, R is 4-(CH3)2CH, R is H,
R5 is lSO-C4H9, R is CH OH, lS
By following the manipulative procedure described above in Example 20, substituting for the reactants used therein molar equivalent amounts of a beta-halo-N-butyryl-2,4,6-triisopropylaniline and l-isobutyl-l-hydroxymethyl-2-hydroxyethylamine, there can be obtained betal-isobuty1-l-hydroxymethyl-2-hydroxyethyl) amino]- N-butyryl-2,4,6-triisopropylaniline.
EXAMPLE 28 Delta-[ (1 -methyI-1 -t-butyl-2-hydroxyethyl amino] -N-ethyl-N-valeryl-Z,6-dimethylaniline R R2 and R are CH3, R3 is H, R4 is C2H5, R5 is t-C4H9, is
By following the manipulative procedure described above in Example 20, substituting for the reactants used therein molar equivalent amounts of a delta-halo-N-ethyl- N-valeryl-Z,6-dimethylaniline and l-methyl-l-t-butyl 2- hydroxyethylamine, there can be obtained delta-[ l-methyl-1-t-butyl-2-hydroxyethyl)amino]-N-ethy1- N valeryl- 2-6-dimethylaniline.
EXAMPLE 29 Gammla- (1 -is0butyl-1-is0pr0pyl-Z-hya'roxyethyl) amino] -N -n-pr0pyl-N -valeryl-2 ,6-dim ethylani line [1; R and R are CH R is H, R; is n-C H R is (CH CH, R is iso-C H Alk is CH CH CH(CH By following the manipulative procedure described above in Example 20, substituting for the reactants used therein molar equivalent amounts of an alpha-methylgamma-halo-N-n-propyl-N-butyryl 2,6 dimethylaniline and l-isobutyl-l-isopropyl-2-hydroxyethylamine, there can be obtained gamma-[(l-isobutyl-1-isopropyl-2-hydroxyethyl)amino]-N-n-propyl-N-valeryl-2,6-dimethylani1ine.
EXAMPLE 30 Epsilon [(I-n-pr0pyl-I-hydr0xymethyI-Z-hydroxyethyl) amino]-N n-butyl-N-aaproyl-4-n-but0xy-2,6-dimethylaniline R1 and R2 are CH3, R3 is 4-I1-C4H90, R4 is I'l-C4H9,
R5 iS Il-C3H 1, R6 is CHZOH, is
By reacting 1,4-dibromobutane with one molar equivalent of diethyl malonate in the presence of an acid-acceptor, for example sodium ethoxide in an ethanol solvent, there can 'be obtained diethyl alpha-(4-bromobutyl) malonate. By heating the latter in aqueous alkali and isolating the product from an acid medium, there can be obtained epsilon bromocaproic acid. By reacting the latter with phosphorus tribromide, there can be obtained epsilon bromocaproyl bromide. By reacting the latter with N-nbuty1-4-n-butoxy-2,-dimethylaniline in the presence of an acid-acceptor according to the manipulative procedure described above in Example 5, there can be obtained epsilon bromocaproyl-N-n-butyl N caproyl 4-n-butoxy-2,6-dimethylaniline. By reacting the latter with l-n-propyl-l-hydroxymethyl-Z-hydroxyethylamine according to the manipulative procedure described above in Example 20, there can be obtained epsilon-[(1-n-propyl-1-hydroxymethy1-2- hydroxyethyl)amino]-N-n-butyl N caprovl-4-n-butoxy- 2,6-dimethylaniline.
13 EXAMPLE 31 A lpha- (1,1 -dimethyl-2-hydroxyethyl) amino] -N-methyl- N -acetyl-4-t-butyl-2,6-dimethylaniline R1, R2, R4, R and R6 are CH3, R3 is 4(CH3)3C,
Alk iS CH By following the manipulative procedure described above in Example 20, substituting for the alpha-chloro- N-acetyl-2,6dimethylaniline used therein a molar equivalent amount of an alpha-halo-N-methyl-N-acetyl-4-t-butyl- 2,6-dimethylaniline, there can be obtained alpha-[(1,1-dimethyl 2 hydroxyethyl)amino]-N-methyl-N-acetyl-4-tbutyl-2,6-dimethylaniline.
EXAMPLE 32 Alpha-[ (1,1-dimethyI-Z-hydroxyethyl) amino] -N-acetyl- 2-ethyl-4-methoxy-6 methylaniline R1, R5 and R6 are CH3, R2 iS C2H5, R3 is 4-CH30,
R iS H, Alk iS CH EXAMPLE 33 Alpha-[ (1,1-dimethyl-Z-hydroxyethyl) amino'] -N-acetyl- 2-t-butyl-6-methyl4-n-propoxyaniline [1; R R and R are CH R is (CH 'C, R is 4-Il-C3H70, R is H, -Alk is CH By following the manipulative procedure described above in Example 20, substituting for the alpha-chloro-N- acetyl-2,6-dimethylaniline used therein a molar equivalent amount of an alpha-halo-N-acetyl-2-t-butyl-6-methyl- 4-n-propoxyaniline, there can be obtained alpha-[(1,1-dimethyl 2 hydroxyethyl)amino] N acetyl-2-t-butyl-6- methyl-4-n-propoxyaniline.
EXAMPLE 34 A lpha-[ (1,1-dimethyl-2-hydroxyethyl) amino] -N-acetyl- 2,6-dimcthyl-4-isopr0pylaniline R1, R2, R5 and R6 are CH3, R3 is 4*(CH3)2CH,
R is H, Alk is CH Alpha- (1,1 -dimethyl-2-hydr0xyethyl) amino] -N-nburyl-N-acetyl-2,3,6-trimethylaniline [1; R1, R2, R5 and R6 are CH3, R3 iS 3-CH3, R4 iS H-C4H9,
Alk is CH By following the manipulative procedure described above in Example 20, substituting for the alpha-chloro-N- acetyl-2,6-dimethylaniline used therein a molar equivalent amount of an alpha-halo-N-n-butyl-N-acetyl-2,3,6- trimethylaniline, there can be obtained alpha-[(l,l-di methyl 2 hydroxyethyl) amino]-N-n-butyl-N-acetyl-2,3, 6-trimethylaniline.
EXAMPLE 36 I A lpha-[ (1,1dimethyl-Z-hydroxyethyl) amino] -N-acetyl- V Z-isopropyl-o-methylaniline R1, R5 and R6 are CH3, R2 iS (CH3)2CH, R3 and R are H, Alk is CH By following the manipulative procedure described above in Example 20, substituting for. the alpha-chloro-N- acetyl-2,6-dimethylaniline used therein a molar equivalent amount of an alpha-halo-N-acetyl-2-isopropyl-6- methylaniline, there can be obtained alpha-[(1,1-dimethyl 2 hydroxyethyl)amino] N acetyl 2 isopropyl-6- methylaniline.
' EXAMPLE 37 Alpha-[ (1,1-dimethyl-2-hydroxyethyl)amino] -N-acetyl- 2,6-diethyl-4-methy[aniline R1 and R2 are C2H5, R3 iS 4-CH3, R4 iS H, R5 and R are CH Alk is CH By following the manipulative procedure described above in Example 20, substituting for the alpha-chloro-N- acetyl-2,6-dimethylaniline used therein a molar equivalent amount of an alpha-halo-N-acetyl-Z,6-diethyl-4-rnethylaniline, there can be obtained alpha-[(1,1-dimethyl-2- hydroxyethyl)amino] N acetyl 2,6-diethyl-4-methylaniline.
EXAMPLE 38 Alpha- (1,1-dimethyZ-Z-hydrovcyethyl)amino] -N-acetyl- 2,4-dimethyl-6-isopropylaniline R1, R5 and R are CH3, R is R3 is 4"CH3,
R is H, Alk is CH Alpha-(4,4-dimethyl-3-0xaz0lidirzyl) -N-acetyl-2,6- dimethylaniline [11; R R R and R are CH R and R, are H, Alk is CH A solution of 7.5 g. (0.03 mole) of alpha-[(1,1-dimethyl 2 hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline and 0.94 g. (0.032 mole) of paraformaldehyde in ml. of dry benzene was heated under reflux using a Dean-Stark trap for separation of the water formed in the reaction. The solution was filtered, the solvent removed under reduced pressure and the residual white solid recrystallized from an ethyl acetate-hexane mixture giving 4.2 g. of alpha (4,4 dimethyl 3 oxazolidinyl) N-acetyl-2,'6-dimethylaniline, M.P. 146.6149.4 C. (corr.).
Analysis.Calcd. for C H N O C, 68.65; H, 8.45; N t Found: C, H, N t l,
Pharmacological evaluation of alpha-(4,4-dimethyl-3- oxazolidinyl) N acetyl-2,6-di-methylaniline in aqueous solution in the form of its acid-addition salts administered intradermally in guinea pigs according to the method of Bulbring and Wajda, ibid., described above, has shown that the compound possesses local anesthetic activity. The Threshold Activity Concentration5 (TAC for the compound Was thus found to be 0.4%
Alpha (4 dimethyl 3 oxazolidinyl) N-acetyl-2,6- dimethylaniline reacts with formic acid, acetic acid, isobutyric acid, alpha-mercaptopropionic acid, malic acid, fumaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, 1- naththalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, Z-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, Z-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, p-toluenesulfonic acid, benzenesulfinic acid, butylarsonic acid, diethylphosphinic acid, p-aminophenylarsinic acid, phenylstibnic acid, phenylphosphinous acid,
methylphosphonic acid, phenylphosphinic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, perchloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrocyanic acid, phosphotungstic acid, molybdic acid, phosphomolybdic acid, pyrohposphoric acid, arsenic acid, picric acid, picrolonic acid, barbituric acid, boron trifluoride, and the like, to give, respectively, the formate, acetate, isobutyrate, alpha-mercaptopropionate, malate' (or acid malate), fumarate (or acid furnarate), succinate (or acid succinate), succinamate, tartrate (or bitartrate), citrate (or acid citrate), lactate, benzoate, 4-methoxybenzoate, phthalate (or acid phthalate), anthranilate, 1-naphthalenecarboxylate, cinnamate, cyclohexanecarboxylate, mandelate, tropate, crotonate, acetylene dicarboxylate, sorbate (or acid sorbate), 2- furancarboxylate, cholate, pyrenecarboxylate, Z-pyridinecarboxylate, 3-indoleacetate, quinate, sulfamate, methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate, benzenesulfinate, butylarsonate, diethylphosphinate, p-aminophenylarsinate, phenylstibnate, phenylphosphinite, methylphosphonate, phenylphosphinate, hydrofiuoride, hydrochloride, hydrobromide, hydriodide, perchlorate, nitrate, sulfate (or bisulfate), phosphate (or acid phosphate), hydrocyanide, phosphotungstate, molybdate, phosphomolybdate, pyrophosphate, arsenate, picrate, picrolonate, barbiturate and boron trifiuoride salts.
Alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl- 2,6-dimethylaniline reacts with hydriodic acid to form alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl 2, G-dimethylaniline hydriodide, useful as a characterizing intermediate.
Alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl- 2,6-dimethylaniline in the form of its hydrodide salt can be converted to the hydrochloride salt by passing an aqueous solution of the former over an ion-exchange resin saturated with chloride ions, for example, Rohm and Haas Arnberlite IRA-400 resin.
Alpha (4,4 dimethyl 3 oxazolidinyl) N acetyl- 2,6-dimethylaniline can be converted to its hydriodide salt and the latter recrystallized for purification purposes from an appropriate organic solvent. On suspension of the hydriodide in dilute aqueous sodium hydroxide, extraction of the suspension with chloroform, and removal of the chloroform from the extracts, alpha-4,4-dimethyl- 3-0xazolidinyl)-N-acetyl-2,6-dimethylaniline can be recovered in purified free base form.
EXAMPLE 4O Alpha-(4-hydr0xymethyl-4-methyl-3-0xaz0lia'inyl) -N- acel'yl-2,6 dimethylaniline [11; R R and R are CH R and R are H,
R5 is CHZOH, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyl)amino] N acetyl 2,6 dimethylaniline used therein a molar equivalent amount of alpha [(1 methyl 1 hydroxymethyl 2 hydroxyethyl)amino]-N-acetyl-2,6-dimethylaniline, there can be obtained alpha-(4 hydroxymethyl 4 methyl-3-oxazolidinyl)-N-acetyl-2,6-dimethylaniline.
EXAMPLE 41 Alpha-[4,4-bis(hydroxymethyl) -3-0xazolidinyl] -N- acetyl-2,6-dimethylaniline [11; R and R are CH R and R are H, R and R are CH OH, Alk is CH By following the manipulative procedure described above in Example 39, substituting for the alpha[(1,1- dimethyl 2 hydroxyethyl)amino] N acetyl 2,6 dimethylaniline used therein a molar equivalent amount of alpha {[l,1 bis(hydroxymethyl) 2 hydroxyethyl] amino}-N-acetyl-2,6-dimethylaniline, there can be ob- 1 6 tained alpha- [4,4-bis (hydroxymethyl) -3-oxazolidinyl] -N- acetyl-2,6-dimethylaniline.
EXAMPLE 42 Beta-(4-melhyl-4-3-0xaz0lidinyl)-N-is0pr0pyl-N- propionylaniline R R2 and R3 are H, R4 is (CH3)2CH, R5 is CH R is CH3CH2, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyl)amino] N acetyl 2,6 dimethylaniline used therein a molar equivalent amount of beta [(1 methyl-l-ethyl-2-hydroxyethyl)-amino]-N- isopropyl-N-propionylaniline, there can be obtained beta (4 methyl 4 ethyl 3 oxazolidinyl) N isopropyl-N-propionylaniline.
EXAMPLE 43 A lpha-(4-elhyl-4-hydroxymethyl-3-0xazolidinyl) -N- etlzyl-N-propionyl-Z-chl0r0-6-methylaniline [11; R is CH R is Cl, R is H, R, and R are C H R is CH OH, Alk is CHCH By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyl)amino] N acetyl 2,6 dimethylaniline used therein a molar equivalent amount of alpha [(1 ethyl 1 hydroxymethyl 2 hydroxyethyl)- amino] N ethyl N propionyl 2 chloro 6 methylaniline, there can be obtained alpha-(4-ethyl-4-hydroxymethyl 3 oxazolidinyl) N ethyl N propionyl 2- chloro-6-methylaniline.
EXAMPLE 44 Gamma- (4-is0pr0py l-4-hydroxymethy 1-3 -0xaz0lidinyl N -n-pr0pyl-N -butyry1-2-br0m0-6-mefhylaniline R1 is CH3, R2 is Br, R3 is H, R4 is n-C H R5 is (CH CH, R iS CH OH, Alk iS (CH By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyl)amino] N acetyl 2,6 dimethylaniline used therein a molar equivalent amount of gamma-[(1 isopropyl l hydroxymethyl-Z-hydroxyethyl)amino1-N-n-propyl N butyryl-2-bromo-6-methylaniline, there can be obtained gamma-(4-isopropyl-4-hydroxymethyl 3 oxazolidinyl) N n propyl N butyryl-2-bromo-6-methylaniline.
EXAMPLE 45 Alpha-methyl-beta-(4,4-dielhyl-3-0xaz0lidinyl)-N-methyl- N-pr0pi0nyl-2,6-dimethy[aniline [11; R R and R are CH R is H, R and R are C H Alk is CH(CH )CH By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyl)amino] N acetyl 2,6 dimethylaniline used therein a molar equivalent amount of alpha methyl beta [(1,l diethyl-2-hydroxyethyl)- amino]-N-methyl-N-propionyl-2,6-dimethylaniline, there can be obtained alpha-methyl-beta-(4,4-diethyl-3-oxazolidinyl -N-methyl-N-propionyl-2,6-dimethylaniline.
EXAMPLE 46 Beta-(4-is0butyl-4-hydr0xymethyl-3-0xaz0lidinyl) N-buryryl-Z,4,6-triis0propylaniline R1 and R2 are (CH3)2CH, R3 is 4"(CH3)ZCH, R4 is H, R iS iSO-C H R is CH OH, Alk iS CH CH(CH By following the manipulative procedure described :above in Example 39, substituting for the alp dimethyl 2-hydroxyethyl) amino]-N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of beta- [(1 isobutyl-1-hydroxymethyl-2-hydroxyethyl)ammo]- r 17 'N-butyryl-ZA,G-t-riisopropylaniline, there can be obtained beta (4 isobutyl-4-hydroxymethyl-3 oxazolidinyl)-N- blltyryl-ZA,6t1=iisopropylaniline.
EXAMPLE 47 Delta- (4 -methyl-4-t-butyl-3-0xaz0tidinyl)-N-ethyl-N Valeryl-2,6-dimethylaniline R1, R2 and R are CH3, R3 is H, R4 iS C2H5,
R5 is t-c H9, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimet-hyl 2-hydroxyethyl)'amino]-N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of delta- [(1-methyl-lat-butyl-2-hydroxyethyl) aam-ino] N ethyl- N-valeryl-Z,6-dimethy1aniline, there can be obtained delta (4 methyl 4 t -butyl-3-oxazolidinyl)-N-ethyl-N- valeryl-2,6-dimethylaniline.
EXAMPLE 48 Gamma? (4 -isob uty l-4-isoprop-y l-3-ovcazolidiny l -N-npro'py'l-N-valeryZ2,6-dimethy[aniline [11; R and R are CH R is H, R, is 11'C3H7, R is (CH3)2CH, R6 is iso-C H is By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dirnethyl 2 hydroxyethyl)amino-N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of gamma- [(1 isobuty-l-l-isopropyl-2-hydroxyethyl)tamino]-N-npropyl N va1eryl-2,6-dimet-hy laniline, there can be obtained gamma (4-isobutyl-4-isopropyl-3-oxazolidinyl)- butoxy-2,6-dimethylaniline.
EXAMPLE 49 Epsilon-(4-n-pr0pyl-4-hydroxymethyl-3-0mzolidinyl)- N -na-bwtyl-N-caproyll-n-butovcy-2,6-dfmethylwniline [11; R and R areCH R is 4-n-C H 0, R is n-C H R5 iS II'C3H7, R6 is CHzOH, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(LL dimethyl Z-hydroxyethyl)amino]-N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of epsilon- [(1 n propyl 1 hydroxymethyl-Z-hydroxyethyl) amino] N n-bu-tyl-N-caproyl-4-n=butoxy 2,6-dimethylaniline, there can be obtained epsilon-(4-n-pr0pyl-4-hydroxy-methyl 3 oxazolidinyl)-N-n-butyl-N caproyl-4-nbutoxy-Z,6-dimethylaniline.
EXAMPLE 50 Alpha-(4,4-dimethyl-3-0xaz0lidinyl) -N-methyl-acetyl- 4-t-butyl-2,6-dimethylaniline R1, R2, R4,IR5 and R6 are CH3, R3 is 4-(CH C, Alk CH By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyhamino] N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of alpha [(1,1-dimethyl-2-hydroxyethyl)amino]-N-methyl- N-acetyl-4-t-butyl-2,6-dimethylaniline, there can be obtained alpha (4,4-dirnethyl-3-0xazolidinyl)-N-methyl- (1,1 dimethyl-Z-hydroxyethyl) amino] -N-acetyl-2-ethyl- 4-methoxy-6-methylaniline, there can be obtained alpha- (4,4 dimethyl 3 oxazolidinyl)-N-acetyl-2-ethyl-4- methoxy-G-methy-laniline.
EXAMPLE 5 2 Alphw-(4,4-dim'efhyl-3-0xaz0lidinyl)-N-acetyl-2-t butyl- 6-methyl-4-n=propoxyaniline R1, R5 and R are CH3, R2 is (CH3)3C, R is 4-Il-C H7O, R4 is H, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dirnethyl 2-hydroxyethyl)amino] -N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of alpha- [(1,1 dimethyl 2 hydroxyethyD-amino]-N acetyl-2- t-butyl-6-methyl-4-n-propoxyaniline, there can be obtained alpha (4,4 dimethyl-3-oxazolidinyl)-N-acetyl-2-t-butyl- 6-methyl-4-n-propoxylani line.
EXAMPLE 5 3 Alphw-(4,4-dfmethyl 3-oxazolidinyl)-N-acetyl-2,6- dimethyl-4-isopropylaniline R1, R2, R5 and R are CH3, is R -iS H, Alk iS CH 1 By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2-hydroxyethy-l) amino] -N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of alpha- [(1,1 dimethyl 2-hydroxyethyl)amino]-N-acetyl-2,6- dime-thyl-4-isopropylaniline, there can be obtained alpha- (4,4 dimethyl 3-oxazolidinyl)-N acetyl-2,6-dimethyl- 4-isopropy1aniline.
EXAMPLE 5 4 A lphal-(4,4-dimethyl-3-0xazolidinyl) -N-n-bmyl-N- acetyl-2,3,6-trimethylaniline R1, -R2, R5 and R6 are CH3, R3 is 3rCH3,
R is n-C H Alk is CH By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2-hydroxyethyl) amino] -N-acetyl-2,6-dimethylaniline used therein :a molar equivalentamount of alpha- 1,l dimethyl- 2-hydroxyethyl)amino]-N-n-butyl-N- acetyl-2,3,G-trimethylaniline, there can be obtained alpha- 4,4 dimethyl 3-oxazolidinyl)-N-n-butyl-N-acetyl-2,3, 6-tr-imethylaniline.
EXAMPLE 55 Alphw-(4,4-dfmethyl-.i-oxazolidinyl) -N-aJcetyl-2- isopropyl-6-methylwniline R1, R5 and R are CH3, R2 is (CH )2CH, R and R are H, Alk is CH,,]
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2-hydroxyethyl)arnino]-N-acetyl-2,6-dimethylaniline used therein a molar equivalent amount of alpha- [(1,1 dimethyl 2-hydroxyethyl)amino] -N acetyl-2- isopropyl-fi-methylaniline, there can be obtained alpha- (4,4 dimethyl-3-oxazolidinyl)-N-acetyl-2-isopropyl-6- methylaniline.
EXAMPLE 5 6 Alpha-(4,4-dimethyl-3-00cz1zolidinyl -N -acetyl-2,6.
diethyl-4-methylani line R1 and R are C2H5, R3 4"CH3, R4 is H, R5 and R are CH3, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl 2 hydroxyethyl)amino] N-acetyl-2,6-dimethy-laniline used therein a molar equivalent amount of alpha-[(Ll dimethyl 2-hydroxyethyl)amino]-N- acetyl 2,6-diethyl-4-methylaniline, there can be obtained 19 alpha (4,4 dimethyl-3-oxazolidinyl)-N-acetyl-2,6-diethyl-4-methylaniline.
EXAMPLE 57 Alpha-(4,4-dimethyl-3-0xaz0lidinyl)-N-acetyl-2,4- dimethyl-6-is0pr0pylaniline R1, R and R3 are CH R2 is (CH3)2CH,
R3 is 4-CH3, R4 iS H, is
By following the manipulative procedure described above in Example 39, substituting for the alpha-[(1,1- dimethyl-Z-hydroxyethyl) a mino]-N-a-cetyl-2,6 dirnethylaniline used therein a molar equivalent amount of alpha- [(1,1 dimethyl-Z-hydroxyethyl)amino]-N-acetyl-2,4-dimethyl-6-isopropylaniline, there can be obtained alpha-(4, 4 dimethyl-3-oxazolidinyl)-N-acetyl-2,4-dimethyl-6-isopropylaniline.
I claim:
1. A member of the group consisting of (A) a compound of the formula R1 R3 fb IIIO O-Alk-NH? CHZOH R4 a R2 and (B) an acid-addition salt thereof wherein R R and R are members of the group consisting of hydrogen, lower-alkyl of from one to four carbon atoms, loweralkoxy of from one to four carbon atoms, and halogen; R represents a member of the group consisting of hydrogen and lower-alkyl of from one to four carbon atoms; R and R are members of the group consisting of loweralkyl of from one to four carbon atoms, and hydroxy methyl; and Alk represents lower-alkylene of from one to five carbon atoms.
2. An acid-addition salt of a compound of the formula I o mon Q-lTf-C O-Alk-NHOI onion H CHzOH Rn wherein R and R each represents lower-alkyl of from one to four cahbon atoms; and Alk represents lower-alkylene of from one to five carbon atoms.
3. An acid-addition salt of a compound of the formula 5 Q-If-C 0-Alk-NH oomon H 51120 H R:
wherein R R and R are lower-alkyl of from one to four carbon atoms; and Alk represents lower-alkylene of from one to five carbon atoms.
4. An acid-addition salt of a compound of the formula References Cited UNITED STATES PATENTS 2,636,038 4/1953 Brandner 260-307 2,715,631 8/1955 Croxall et a1. 260-307 2,793,155 5/1957 Smith et a1. 260-562 2,830,087 4/1958 Ehrhart et al. 2 -562 2,987,519 6/1961 Zenitz 260-307 3,042,720 7/1962 Paabo 260-562 FOREIGN PATENTS 634,073 3/ 1960 Great Britain. 726,080 3/ 1955 Great Britain.
OTHER REFERENCES Elderfield: Heterocyclic Compounds N.Y., Wiley, 1957 vol. 5, pages 391-2.
Lofgren et al.: Svensk, Kern. Tidskr., vol. 58, pages 323-335, pages 326, 331 relied on (1946).
WALTER A. MODANCE, Primary Examiner.
H. J. LIDOFF, V. J. MCCUTCHEN, N. R. RIZZO,
Examiners.
N. TROUSOF, J. W. ADAMS, R. L. =PRICE,
Assistant Examiners.
UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No 3 ,334 ,100 August 1, 1967 Bernard L. Zenitz It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.
R column 4 line 31 for "carboxylic" read carboxylic line 33 for "ion exchange" read ion-exchange column 6, line 18, for "9:38" read 9.38 line 35, for read column 8, line 31, for "for" read of column 12, line 33 for "2-6" read 2 6 column 15 line 5 for "py'rohposph'oric" read pyrophosphoric column 16 line 4 for "Beta-(4-methyl-4-3-" read Beta- (4-methyl-4- Column 1 line 49 for "R R read R ethyl-3- column 17, line 33, for "butoxy2,6dimethylaniline" read N-n-propyl-N-valeryl-Z,G-dimethylaniline column 19, line 44, for "cahbon" read carbon Signed and sealed this 22nd day of April 1969.
(SEAL) Attest:
EDWARD M.FLETCHER,JR. EDWARD J. BRENNER Attesting Officer Commissioner of Patents
Claims (1)
1. A MEMBER OF THE GROUP CONSISTING OF (A) A COMPOUND OF THE FORMULA
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23919A US3334100A (en) | 1960-04-22 | 1960-04-22 | Amino-lower-alkanoylanilines |
| US196027A US3152140A (en) | 1960-04-22 | 1962-05-04 | 3-oxazolidino-lower-alkanoylanilines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23919A US3334100A (en) | 1960-04-22 | 1960-04-22 | Amino-lower-alkanoylanilines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3334100A true US3334100A (en) | 1967-08-01 |
Family
ID=21817923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US23919A Expired - Lifetime US3334100A (en) | 1960-04-22 | 1960-04-22 | Amino-lower-alkanoylanilines |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US3334100A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931314A (en) * | 1972-05-12 | 1976-01-06 | Cassella Farbwerke Mainkur Aktiengesellschaft | Benzophenone derivatives and process for their production |
| US4510340A (en) * | 1982-07-08 | 1985-04-09 | International Flavors & Fragrances, Inc. | Methyl substituted pinyl oxopentenes, organoleptic uses thereof and process for preparing same |
| US4526788A (en) * | 1983-03-18 | 1985-07-02 | American Cyanamid Company | Polymeric[[(oxazolidinyl)alkyl]amino]anthraquinones |
| CN114948953A (en) * | 2021-06-29 | 2022-08-30 | 四川大学华西医院 | Heteroatom substituted aromatic compound and application of salt thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB634073A (en) * | 1944-05-25 | 1950-03-15 | Astra Apotekarnes Kem Fab | Process for the preparation of local anaesthetics |
| US2636038A (en) * | 1951-05-18 | 1953-04-21 | Atlas Powder Co | Surface active agents |
| GB726080A (en) * | 1952-02-25 | 1955-03-16 | Cilag Ltd | New halogen-containing amino fatty acid anilides, their addition salts and their production |
| US2715631A (en) * | 1952-12-23 | 1955-08-16 | Rohm & Haas | Aminomethyloxazolidines |
| US2793155A (en) * | 1956-02-24 | 1957-05-21 | Geistlich Soehne Ag | Anaesthetic compositions |
| US2830087A (en) * | 1955-02-21 | 1958-04-08 | Hoechst Ag | beta-hydroxybutyric acid para-phenetidide and a process for preparing it |
| US2987519A (en) * | 1959-11-09 | 1961-06-06 | Sterling Drug Inc | 3-alkyl-4, 4-bis (hydroxymethyl)-oxazolidines and process for the preparation thereof |
| US3042720A (en) * | 1959-05-18 | 1962-07-03 | Fine Chemicls Of Canada Ltd | Hydroxy-alkyl-aminoacetyl xylidides |
-
1960
- 1960-04-22 US US23919A patent/US3334100A/en not_active Expired - Lifetime
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB634073A (en) * | 1944-05-25 | 1950-03-15 | Astra Apotekarnes Kem Fab | Process for the preparation of local anaesthetics |
| US2636038A (en) * | 1951-05-18 | 1953-04-21 | Atlas Powder Co | Surface active agents |
| GB726080A (en) * | 1952-02-25 | 1955-03-16 | Cilag Ltd | New halogen-containing amino fatty acid anilides, their addition salts and their production |
| US2715631A (en) * | 1952-12-23 | 1955-08-16 | Rohm & Haas | Aminomethyloxazolidines |
| US2830087A (en) * | 1955-02-21 | 1958-04-08 | Hoechst Ag | beta-hydroxybutyric acid para-phenetidide and a process for preparing it |
| US2793155A (en) * | 1956-02-24 | 1957-05-21 | Geistlich Soehne Ag | Anaesthetic compositions |
| US3042720A (en) * | 1959-05-18 | 1962-07-03 | Fine Chemicls Of Canada Ltd | Hydroxy-alkyl-aminoacetyl xylidides |
| US2987519A (en) * | 1959-11-09 | 1961-06-06 | Sterling Drug Inc | 3-alkyl-4, 4-bis (hydroxymethyl)-oxazolidines and process for the preparation thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3931314A (en) * | 1972-05-12 | 1976-01-06 | Cassella Farbwerke Mainkur Aktiengesellschaft | Benzophenone derivatives and process for their production |
| US4510340A (en) * | 1982-07-08 | 1985-04-09 | International Flavors & Fragrances, Inc. | Methyl substituted pinyl oxopentenes, organoleptic uses thereof and process for preparing same |
| US4526788A (en) * | 1983-03-18 | 1985-07-02 | American Cyanamid Company | Polymeric[[(oxazolidinyl)alkyl]amino]anthraquinones |
| CN114948953A (en) * | 2021-06-29 | 2022-08-30 | 四川大学华西医院 | Heteroatom substituted aromatic compound and application of salt thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3960886A (en) | Substituted N-arylanilines | |
| US3334100A (en) | Amino-lower-alkanoylanilines | |
| US3479346A (en) | N-acyl-n- (and n,n-bis-) ((1-piperidyl)-lower-alkyl)amines | |
| US3264309A (en) | N' [nu-(monocarbocyclic aryl) carbamyllower-alkyl]-1, 5-iminocycloalkanes, -iminocycloalkenes and related compounds | |
| US3984467A (en) | Anthelmintic 1-(substituted phenyl)-3-alkanimidoyl ureas | |
| US3719674A (en) | 1,2-substituted indene compounds | |
| US3394181A (en) | Phenoxy-lower-alkyl-amidoximes and phenylamino-lower-alkyl-amidoximes | |
| US3365453A (en) | 1-phenyl-4-lower-alkyl-2-piperazinones | |
| US4183930A (en) | Amino derivatives of pyrazolo [1,5-a]s-triazine, and their therapeutic applications | |
| US4242348A (en) | Novel basic substituted-alkylidenamino-oxylalkyl-carboxylic-acid esters | |
| US3152140A (en) | 3-oxazolidino-lower-alkanoylanilines | |
| US3547937A (en) | Certain 4-thiazolecarboxamidines | |
| KR880001477B1 (en) | Process for preparing niflumic acid morpholinoethyl ester diniflumate | |
| CA1129875A (en) | Chromone derivatives | |
| DE2303427C3 (en) | Dibenzo- (a, d) -cycloheptadienes and -trienes, processes for their preparation and pharmaceuticals containing these compounds | |
| US2822391A (en) | Conhj | |
| DE2623314A1 (en) | NEW 1-ARYLOXY-2-HYDROXY-3-AMINOPROPANES AND THE METHOD FOR THEIR PRODUCTION | |
| US3860582A (en) | Derivatives of 4-chloro-5-sulfamoyl-anthranilic acid | |
| DE2330124A1 (en) | ANILIDE DERIVATIVES, THEIR SALTS, PROCESS FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS | |
| US3419559A (en) | 5-substituted-2-oxazolidinones | |
| US3202675A (en) | 1-benzyl-2, 5-bis (chloromethyl) pyrrolidine and acid-addition salts thereof | |
| DE2609862C2 (en) | ||
| US3963748A (en) | 1-Phenyl-3-azacarbocyclic-ureas | |
| US3225091A (en) | Anticholinergic substituted butyramides | |
| US3790631A (en) | Carbimidoyl ureas |